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1	 	 DEFINING	THE	NOTCH1-REGULATED	LNCRNAOME	IN	T-ALL	 89	
PAPER	1	 The	Notch	driven	long	non-coding	RNA	repertoire	in	T-cell	acute	lymphoblastic		








































































































































































































































































opment	 in	the	thymus	and	to	an	overpopulation	of	 immature	T-cells	 in	the	blood	stream	and	
infiltration	 of	 lymphoblasts	 in	 the	 bone	marrow.	 These	 immature	 T-cell	 lymphoblasts	 do	 not	
have	the	potential	to	fight	infections	as	normal	T-cells	have	and	since	they	overpopulate	other	
cell	 types	 in	 the	 blood,	 these	 cells	 cannot	 function	 either.	 Clinical	 consequences	 of	 this	 per-
turbed	blood	cell	maturation	are	fatigue,	shortness	of	breath,	multiple	infections,	bruising	and	
easy	bleeding	and	the	presence	of	mediastinal	thymic	masses.	
In	 pediatric	 cancers,	 acute	 lymphoblastic	 leukemia	 is	 the	 most	 prevalent	 malignancy.	 T-cell	

























development	are	also	 known	as	 “double	negative”	 thymocytes.	 To	 induce	T-cell	 specification	























After	 T-cell	 commitment,	 the	next	 step	 in	 T-cell	 development	 is	 called	β–selection	which	de-




great	 diversity	 of	 antigens	 that	 can	be	detected	by	 T-cells.	 The	RAG	mediated	double	 strand	
breaks	place	the	cells	undergoing	V(D)J	recombination	in	a	vulnerable	position,	exposing	them	






































ing.	Next	 to	 that,	 hierarchical	 clustering	of	 expression	profiles	 allowed	 the	 identification	of	 a	
new	subgroup	that	clustered	close	to	the	TLX1	group	and	was	marked	by	high	expression	levels	
of	 ‘T-cell	 leukemia	Homeobox	3’	 (TLX3/HOX11L2)15.	 A	 second	 important	 study	by	 the	 Soulier	
team	detected	a	subset	of	patients	with	an	unknown	disease	mechanism,	which	clustered	in	a	
separate	 group,	 but	 near	 the	TLX1	 and	TLX3	 samples.	 All	 patient	 samples	 in	 this	 cluster	 had	
markedly	elevated	expression	levels	of	HOXA	genes,	resulting	from	a	recurrent	cryptic	chromo-
somal	 rearrangement16.	 In	 addition,	 T-ALL	 samples	 with	 an	 immature	 immunophenotype	
(strong	CD34	expression)	also	marked	a	separate	cluster.	
These	two	papers	thus	detected	new	oncogenic	T-ALL	transcription	factors	by	means	of	gene	






















































cus	 and	 less	NOTCH1	 activating	mutations20.	 The	 prevalence	 of	 immature	 T-ALL	 is	 higher	 in	
adult	patients	compared	to	pediatric	cases	and,	remarkably,	some	of	the	oncogenic	mutations	
involved	 in	 immature	T-ALL	development	 (ex.	DNMT3A)	 are	only	present	 in	adult	T-ALL	 sam-
ples21.			
A	part	of	the	immature	T-ALL	cases,	with	a	differentiation	arrest	at	the	ETP-stage	of	T-cell	de-
velopment,	 can	 be	 further	 subclassified	 into	 early	 T-cell	 precursor	 ALL	 (ETP-ALL).	 ETP-ALL	 is	
characterized	by	the	absence	of	expression	of	CD1a	and	CD8,	weak	expression	of	CD5	and	the	
expression	of	 one	or	more	 stem	cell	 or	myeloid	markers	 (CD117,	CD34,	CD13,	CD33,	CD11b,	
CD65	and/or	HLA-DR),	resembling	a	bi-phenotypic	nature22.	Using	whole	genome	sequencing,	
Zhang	et	al.	established	a	comprehensive	genomic	picture	of	the	mutational	landscape	of	ETP-
ALL	 characterized	by	 inactivating	mutations	 in	 genes	 involved	 in	hematopoietic	 development	
(RUNX1,	GATA3,	BCL11B,	ETV6…),	activating	mutations	of	mediators	of	 cytokine	 receptor	 sig-
naling	and	RAS	signaling	(NRAS,	KRAS,	IL7R,	JAK1	…)	and	various	genetic	lesions	affecting	epige-
netic	regulators,	most	notably	the	‘Polycomb	Repressive	Complex	2’(PRC2)	components	EZH2,	
SUZ12	 and	 EED23.	 Of	 further	 interest,	 some	 adult	 ETP-ALL	 patients	 also	 show	 high	 levels	 of	
DNMT3A,	 IDH1	 and	 IDH2,	 which	 are	 known	 oncogenes	 in	 acute	 myeloid	 leukemia	 (AML)	 in	
keeping	with	the	bi-phenotypic	nature	of	ETP-ALL24.	
In	 addition	 to	 the	 early	 studies	 describing	 high	 expression	 levels	 for	 presumed	oncogenes	 in	
immature	T-ALL,	more	 recently	 yet	another	driver	gene	was	added	 to	 the	 list.	Unexpectedly,	
Goossens	et	al.	observed	T-cell	malignancies	with	 immature	characteristics	 in	a	mouse	model	
with	Zeb2	gain-of-function	in	a	p53	knock	out	genetic	background.	Together	with	the	finding	of	
rare	translocations	juxtaposing	ZEB2	 in	the	vicinity	of	the	BCL11B	 locus,	 leading	to	ZEB2	over-
expression	and	BCL11B	downregulation,	this	provided	strong	support	for	an	oncogenic	role	of	















a	 TLX1	 overexpressing	mouse	model.	 After	 a	 long	 latency,	 these	mice	 developed	 T-cell	 neo-
plasms	with	a	high	degree	of	aneuploidy	and	defects	in	the	mitotic	checkpoints.	Furthermore,	it	
was	 shown	 that	 TLX1	 overexpression	 caused	 inhibition	 of	 T-cell	 differentiation	 and	 required	
additional	 genetic	 events	 for	 further	 T-ALL	 oncogenesis	 such	 as	Notch1	 activating	 and	 Pten,	
Tp53	and	Bcl11b	inactivating	mutations28.	A	remarkable	finding	was	done	by	Durinck	et	al.	who	
studied	the	genome-wide	binding	of	TLX1	in	T-ALL	and	observed	an	unexpected	attenuation	of	
















The	 TAL-rearranged	 (TAL-R)	 subtype	 represents	 T-ALLs	 arising	 through	 overexpression	 of	
E2A/HEB	transcription	factors	due	to	unscheduled	constitutive	TAL1,	LYL1	or	LMO2	activation	
during	thymopoiesis.	TAL1	was	first	discovered	through	the	rare	translocations	t(1;14)(p32;q11)	
and	 t(1;7)	 (p32;q35))37,	 leading	 to	 the	 juxtaposition	 of	 TAL1	 near	 strong	 enhancers	 of	 the	
TCRα/TCRδ	or	TCRβ	loci.	Subsequently,	a	highly	recurrent	cryptic	interstitial	1p32	deletion	was	
detected	in	25%	of	T-ALL	cases,	placing	TAL1	under	the	control	of	the	STIL	promotor37.	The	class	
B	 helix-loop-helix	 (bHLH)	 protein	 TAL1	binds	 LIM-domain	only	 proteins	 (LMO1	or	 LMO2)	 and	
overexpression	of	these	LMO	genes	themselves	is	a	second	mechanism	linked	to	this	T-ALL	sub-
type.	Typically,	LMO1/2	activation	is	detected	in	10%	of	T-ALL	cases	and	results	from	TCR	medi-
















The	HOXA	 subgroup	 is	 typically	marked	 by	 cases	with	 illegitimate	 TCR	 rearrangement	 driven	
HOXA	 gene	 cluster	 activation.	 The	 prototypical	 rearrangement	 is	 a	 pericentric	 inversion	 of	
chromosome	7	(inv(7)(p15q34))	which	was	shown	to	activate	several	HOXA	cluster	genes,	most	
notably	HOXA9,	HOXA10	and	HOXA11,	and	presents	with	a	mature	immunophenotype	of	either	
the	αβ-	 or	 the	 γδ-lineage16,	47.	 In	 addition	 to	HOXA	 cluster	 rearranged	 cases,	HOXA	gene	up-
regulation	could	also	result	from	other	oncogenic	events	through	e.g.	formation	of	the	CALM-

































































sequencing	 efforts,	 have	 provided	 a	 detailed	 view	 on	 the	 plethora	 of	 oncogenes	 and	 tumor	
suppressors	 implicated	 in	 this	 complex	 process63.	 Of	 these,	 one	 of	 the	most	 frequently	 per-
turbed	pathways	 is	 controlled	by	NOTCH1,	known	 to	play	multiple	crucial	 roles	 in	controlling	
normal	 T-cell	 development10,	64-70	with	 overactivation	 of	NOTCH1-signaling	 being	 observed	 in	














	 Oncogenic	lesion	 Frequency	 Ref	
Oncogenes	
NOTCH1	 Activating	mutation	 >	60	%	 71	
IL7R	 Activating	mutation	 10	%	 80,	81	







CDKN2A/2B	 9p21	deletion	 >	70	%	 72	
PHF6	 Inactivating	 mutation	 or	 dele-
tion	
20-40	%	 74	
FBXW7	 Inactivating	mutation	 10-30	%	 83,	84	
RUNX1	 Inactivating	 mutation	 or	 dele-
tion	
10-20%	 85,	86	








BCL11B	 Inactivating	 mutation	 or	 dele-
tion	
10	%	 87	
SUZ12	 Inactivating	 mutation	 or	 dele-
tion	
10	%	 23	








cellular	 environment	 directly	 into	 changes	 in	 gene	 expression.	 NOTCH1	 is	 a	 heterodimeric	








acetyltransferases	 (CBP/p300)89.	 FBXW7,	 an	 E3-ubiquitin	 ligase,	 terminates	NOTCH1-signaling	
due	 to	 the	 recognition	 of	 the	 PEST-domain	 in	 ICN1,	 which	 leads	 to	 its	 proteasomal	
degradation84.	In	the	absence	of	ICN1,	RBPJκ	associates	with	co-repressors	that	recruit	histone	
deacetylases	(HDACs),	repressing	the	activation	of	NOTCH1	target	genes90.	(Figure	3)		
Notch	signaling	 is	 involved	 in	development	and	cellular	processes	 in	several	 tissues,	 including	











Figure	3.	NOTCH1-signaling	pathway.	The	 interaction	of	 the	NOTCH1	receptor	on	the	surface	of	 the	early	T-cell	
progenitors	(Receiving	Cell)	with	the	DLL4	ligand	expressed	on	the	surface	of	thymic	stroma	cells	(Sending	Cell)	re-
sults	in	proteolytic	cleavage	of	the	receptor.	The	intracellular	domain	of	NOTCH1	(ICN1)	is	released	from	the	mem-
brane	and	 translocates	 to	 the	nucleus,	where	 it	 interacts	with	RBPJ	and	MAML1.	This	complex	activates	 the	ex-
pression	of	NOTCH1	target	genes,	leading	to	cell	differentiation,	T-cell	lineage	commitment,	proliferation	and	sur-
vival.	The	termination	of	NOTCH1	signaling	is	mediated	by	FBXW7.	The	NOTCH1	signaling	pathway	can	be	thera-
peutically	 targeted	 through	 GSI	 (γ-secretase	 inhibitor)	 based	 blocking	 of	 the	 γ-secretase	 cleavage,	 antibodies	














































































treatment	 was	 the	 dose-limiting	 gastrointestinal	 toxicity,	 resulting	 from	 the	 inhibition	 of	
NOTCH1	and	NOTCH2	in	the	intestinal	progenitor	cells107.	Various	drug	combinations	with	GSIs	
were	 tested	 to	 look	 for	 drugs	 that	 could	 alleviate	 the	 side	 effects	 and	 glucocorticoids	 were	
identified	as	a	candidate.	Combination	regimens	with	chemotherapy	or	drugs	 targeting	other	
pathways	 involved	 in	T-ALL	 (ex.	NF-κB	signaling103,	PI3K-AKT-mTOR	 inhibitors108	and	HDAC	 in-
hibitors109)	could	also	be	used.	Other	therapeutic	options	would	be	the	use	of	an	antibody	that	
specifically	blocks	 the	NOTCH1	 receptor110,	 the	 inhibition	of	 the	ADAM	metalloprotease111	or	
the	inhibition	of	the	ICN1-RBPJκ-MAML1	transcriptional	complex	by	a	peptide	called	SAHM1112.	
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with	 the	 idea	he	 called	 “The	 central	 dogma”.	 This	 theory	 states	 that	DNA	 is	 transcribed	 into	
RNA,	which	is	then	translated	into	protein,	the	molecule	with	the	active	function,	and	that	the	
information	cannot	be	 transferred	back	 from	protein	 to	nucleic	acid6.	 It	was	 just	a	 few	years	
later	 that	 the	 first	 RNA	molecule	with	 a	 function	by	 itself	was	described	by	R.W.	Holley,	 the	
tRNA3,	4.	A	tRNA	is	the	adaptor	between	the	mRNA	and	the	amino	acid	sequence	of	proteins,	




Since	 the	 discovery	 of	 DNA,	 RNA	 and	 proteins,	molecular	 biology	 research	 has	 boomed	 and	
more	 functional	 noncoding	 RNA	molecules	were	 discovered	 to	 be	 involved	 in	 several	 crucial	
pathways	 in	the	cell.	Most	of	these	RNAs	are	now	characterized	as	small	noncoding	RNAs,	as	
they	are	not	longer	than	200	nucleotides.	DNA	replication	makes	use	of	the	small	noncoding	Y	
RNAs	 for	 their	 interaction	with	 chromatin	 and	 initiation	proteins10 and	 these	 Y	RNAs	 are	 re-
quired	for	cell	proliferation	in	tumors11.	Furthermore,	small	nuclear	RNAs		(snRNAs)	are	part	of	
the	spliceosome,	having	a	role	in	pre-mRNA	splicing12	and	small	nucleolar	RNAs	(snoRNAs)	are	





spermatogenesis	and	 function	by	guiding	the	PIWI	proteins	 to	 transposons	to	 induce	their	si-
lencing15.	 Another	 example	 of	 small	 ncRNAs	 are	 microRNAs	 which	 are	 involved	 in	 post-
transcriptional	gene	regulation,	this	type	of	ncRNAs	will	be	discussed	in	more	detail	in	section	






chromosomes.	 The	 TERC	RNA	of	 this	 complex	 is	 over	 500	 nucleotides	 in	 size	 and	 has	 a	 dual	
function.	It	acts	as	a	scaffold	for	several	proteins	of	the	complex	and	it	also	contains	the	tem-
plate	RNA	sequence	for	DNA	synthesis	by	the	Telomerase	Reverse	Transcriptase	(TERT)19.	In	the	
last	 decade,	 much	 work	 has	 been	 done	 on	 the	 so-called	 long	 noncoding	 RNAs	 (lncRNAs),	
noncoding	 RNA	 molecules	 with	 a	 length	 of	 at	 least	 200	 nucleotides,	 and	 several	 of	 these	






further	 established	 the	 importance	 of	 the	 noncoding	 DNA.	 They	 showed	 that	 the	 ratio	 of	
noncoding	DNA	to	the	full	genomic	sequence	could	explain	the	complexity	of	species,	with	low	

































































lar	 miRNAs	 have	 and	 the	 variety	 of	 different	 miRNAs	 that	 can	 bind	 the	 3’UTR	 of	 specific	
mRNAs30.		





























peting	endogenous	RNA”	 (ceRNA),	 compete	 for	 the	miRNA	binding,	 leading	 to	an	 increase	 in	
expression	of	the	target	gene35.		
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and	 novel	 sequencing	 technologies55,	 56,	 fueled	 the	 discovery	 of	 novel	 long	 noncoding	 RNA	
(lncRNA)	 genes.	 Since	 then,	 several	 microarray	 hybridization	 and	 deep	 sequencing	 analyses	
provided	further	in	depth	studies	and	now	it	is	estimated	that	at	least	roughly	75%	of	the	hu-
man	genome	 is	 transcribed24.	While	 this	 finding	 is	overwhelming,	most	 lncRNAs	remain	 func-
tionally	unannotated	and	 it	 remains	to	be	determined	how	many	 lncRNAs	effectively	execute	
specific	cellular	functions.		
More	 evidence	 supporting	 the	 transcription	 of	 ncRNAs	 came	 from	 the	 epigenetics	 field	 that	
profiled	 specific	histone	markers	across	 the	genome	and	discovered	methods	 to	detect	open	
(or	active)	chromatin.	Several,	but	not	all,	of	the	previously	detected	ncRNAs	were	character-
ized	by	DNase1	hypersensitivity,	active	chromatine	marks	(ex.	H3K4me3	marks	at	the	promoter	




Even	 before	 these	 large	 scale	 studies,	 some	 lncRNAs	 were	 already	 discovered.	 In	 the	 early	
1990s	H19	and	XIST	were	detected	as	 lncRNAs	with	a	role	 in	epigenetic	regulation20,	21,	63	and	
also	 the	 TERC	 RNA	 of	 the	 telomerase	 complex	 was	 well	 known19.	 Since	 2010,	 research	 on	









The	 latter	 characteristic	 offers	 perspectives	 for	 lncRNAs	 as	 potential	 targets	 for	 therapy,	 as	
their	specific	expression	pattern	might	avoid	off-target	effects	of	specific	lncRNA	inhibitors.	
One	possible	classification	of	lncRNAs	is	based	on	the	location	of	the	lncRNA	gene	in	compari-
son	 to	 protein	 coding	 genes	 (Figure	 6).	 Intergenic	 lncRNAs	or	 ‘lincRNAs’	 do	not	 overlap	with	
protein	coding	genes.	As	 these	 lincRNAs	are	quite	easy	 to	define,	 the	 first	described	 lncRNAs	







of	 the	 Flowering	 Locus	 C	 (FLC)	 gene	 and	 is	 necessary	 for	 the	 epigenetic	 repression	 of	 FLC	
through	the	recruitment	of	PRC2	(Polycomb	Repressive	Complex	2)68.	The	third	class	of	lncRNAs	
includes	the	lncRNA	genes	that	overlap	with	a	known	protein-coding	gene	in	the	antisense	di-
rection,	of	which	HOTAIR	 (HOX	transcript	antisense	RNA)	 is	a	well-known	example.	HOTAIR	 is	















or	epigenetic	 regulators	and	"guide"	them	to	a	genomic	 location	 (ex.	XIST	and	the	epigenetic	
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very	 specific	 expression	 patterns.	 One	 landmark	 study	 by	 the	 group	 of	 John	 Rinn	 made	 18	
knockout	 mouse	 models	 of	 intergenic	 lncRNAs	 that	 were	 conserved	 between	 humans	 and	
mice77.	Three	homozygous	knockout	models	were	incompatible	with	life,	showing	an	important	
role	for	the	 lncRNA	in	viability	 (Fendrr-/-,	Peril-/-	and	Mdgt-/-)	and	two	other	 lncRNA	knockouts	




lncRNA	 Function	 Mechanism	 Mouse	models	 Ref.	
Fendrr	 ?	 Interacts	with	PRC2	 Knockout	 is	 perinatally	
lethal	due	to	respirato-
ry	defects		




H19	 Allelic	 imprinting	 at	 the	
IGN	 locus	 (Imprinted	
Gene	Network)	






HOTAIR	 Inactivation	 of	HOXD	 lo-










HOTTIP	 Activation	 of	 5’	 HOXA	
genes	
Recruits	 the	WDR5/MLL	 complex	 by	










Modulates	 nuclear	 speckle	 associa-
tion	of	various	splicing	factors	
Interaction	 with	 chromatin	 readers	
at	genome	loci	
Knockdown	 has	 no	 ef-





Interacts	 with	 paraspeckle	 proteins	
and	transcriptional	repressors	










XIST	 Inactivation	 of	 one	 of	
the	X	chromosomes	
Recruits	PRC2	(H3K27	trimethylation)	 Partial	 deletion	 is	 em-










Together	 with	 the	 discovery	 of	 lncRNAs	 playing	 a	 role	 in	 normal	 cell	 homeostasis,	 several	
lncRNAs	were	discovered	with	a	differential	expression	pattern	 in	one	or	more	cancer	 types.	
Some	identified	cancer-related	lncRNAs	also	had	a	function	in	normal	development,	but	several	
were	 only	 expressed	 in	 that	 specific	 cancer	 type,	making	 them	 ideal	 candidates	 for	 targeted	
therapy.	Furthermore,	lncRNAs	were	described	as	biomarkers	for	cancer	type,	stage	or	progno-
sis.	Still	most	of	the	cancer-associated	lncRNAs	are	only	identified	based	on	expression	profiling	









































cogenic	 process.	 Challenges	 for	 in	 vitro	 studies	 include	 low	 success	 rates	 of	 shRNA/siRNA-
mediated	knockdown	as	the	RNAi	machinery	is	present	in	the	cytoplasm	and	most	lncRNAs	are	
localized	 in	 the	 nucleus,	 but	 also	 the	 uncertainty	 of	 the	 annotation	 of	 lncRNA	 transcript	 se-
quence	and	cis-regulatory	functions	make	overexpression	challenging.	Furthermore,	poor	spe-
cies	conservation	for	many	lncRNAs	often	precludes	in	vivo	studies.	These	challenges	and	solu-
tions	are	discussed	 in	more	detail	 in	 the	 review	 in	 the	next	part	of	 this	 introduction.	Despite	
these	 challenges,	 several	 lncRNAs	 could	 convincingly	 be	 linked	 to	 several	 cancer	 processes,	
such	as	the	melanoma-specific	 lncRNA	SAMMSON	 (as	discussed	in	Box	2	 in	more	detail)98.	An	
overview	of	a	selection	of	lncRNAs	with	a	role	in	cancer	can	be	found	in	Table	4.	It	should	how-



























Table	 4.	 Long	 noncoding	 RNAs	 with	 an	 oncogenic	 or	 tumor	 suppressor	 role	 in	 cancer.	 Inspired	 by	 recent	
reviews96,	99.	(A	list	of	abbreviations	can	be	found	at	the	beginning	of	this	thesis.)		
	
lncRNA	 Cancer	assocation	 Mechanism	 Phenotype	 Ref.	
ANRIL	 High	 expression	 in	 prostate	 can-





CCAT1	 Oncogenic	 in	 gastric,	 colorectal	
and	gall	bladder	cancer	







CRNDE	 Upregulated	 in	 colorectal	 cancer,	
glioma,	liver	cancer,	medulloblas-
toma	…	
Interacts	 with	 PRC2,	 reduces	








GAS5	 Downregulated	 in	 breast,	 pros-



















metastatic	 breast,	 lung	 and	 pan-
creatic	cancers	
Silencing	 of	 HOXD	 and	 other	
genes	 through	 PRC2	 and	 LSD1	
binding	
é metastasis	 82,	 123-
128	




















MALAT1	 Overexpressed	 in	 several	 cancer	
types	 (colorectal,	 breast…).	 SNP	










Recruits	 PRC2	 for	 gene	 silenc-
ing.	 Regulates	 TGF-β	 pathway	
genes.	
ê 	proliferation 136-139	















lncRNA	 Cancer	assocation	 Mechanism	 Phenotype	 Ref.	
NEAT1	 Upregulated	 in	 several	 cancer	











PCA3	 Biomarker	for	prostate	cancer	 Androgen	 receptor	 signaling	
modulation	
é 	cell	survival	 141,	142	
PCAT1	 Upregulated	 in	 prostate	 cancer	
with	disease-associated	SNPs	
Recruits	 PRC2	 for	 gene	 silenc-




PCGEM	 Upregulated	in	prostate	cancer	 Androgen	 receptor	 transcrip-





Sponge	 for	 miRNAs	 targeting	



















and	 cervical	 cancer,	 testicular	















































































In	 the	 first	 study,	 neither	 the	 sequence	 nor	 the	 transcription	 of	 3	 cis-acting	 lncRNAs	 influ-
enced	the	expression	of	the	neighboring	genes.	It	appeared	that	only	the	DNA	regulatory	el-











effects.	 Furthermore,	 it	was	 shown	 that	Uph	 transcription	was	necessary	 for	 the	H3K4me1	







Several	 lncRNAs	are	known	to	be	specifically	expressed	 in	a	certain	cancer	 type,	without	any	
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acute	 lymphoblastic	 leukemia,	 which	 is	 a	 malignant	 blood	 disorder	 arising	 from	 oncogenic	
events	during	normal	T-cell	development	in	the	thymus.	By	studying	the	transcriptomic	profile	
of	protein	coding	genes,	several	oncogenic	events	leading	to	T-ALL	could	be	identified.	In	recent	
years,	 it	 became	 apparent	 that	 several	 of	 these	 oncogenes	 function	 via	microRNAs	 and	 long	








consist	 of	 several	 distinct	 families	 including	microRNAs,	 small	 nuclear	 RNAs,	 PIWI-interacting	
RNAs	and	long	noncoding	RNAs.	 Interestingly,	the	detection	of	noncoding	RNAs	 led	to	a	solu-
tion	 for	 the	G-value	paradox	 that	 states	 that	 there	 is	 no	 correlation	between	 the	 amount	of	
coding	 genes	and	 the	 complexity	of	 the	organism	 [2],	while	we	do	observe	a	 correlation	be-
tween	the	complexity	of	the	organism	and	the	ratio	of	the	amount	of	noncoding	genes	to	the	



































pressed	by	p53	 [19-21]	and	controls	a	plethora	of	 target	genes	 including	PTEN,	BIM	 and	p21	
(CDKN1A),	 thereby	broadly	 impacting	on	 the	phenotype	of	 cells	 [22,	23].	One	of	 the	 first	de-
scribed	tumor	suppressor	miRNAs	is	encoded	by	the	miR-15a/16-1	cluster	and	this	locus	is	af-
fected	by	 recurrent	13q14	deletions	 in	more	 than	half	of	 chronic	 lymphocytic	 leukemia	 (CLL)	
cases	with	the	BCL2	oncogene	as	a	primary	target	[24,	25].	Following	these	landmark	discover-
ies,	many	additional	miRNAs	have	been	identified	to	act	as	oncomirs	or	tumor	suppressor	miR-
NAs	 (reviewed	 in	 [16,	 26,	 27]).	 Recent	 studies	 also	 linked	 another	 class	 of	 small	 noncoding	
RNAs,	the	PIWI-interacting	RNAs	(piRNAs)	to	cancer.	PiRNAs	were	detected	to	be	upregulated	
in	several	cancer	types,	which	could	be	linked	to	a	poor	prognosis.	The	specific	mechanism	of	












While	 the	 existence	of	 certain	 long	noncoding	RNAs	 (lncRNAs)	 such	 as	XIST	 (implicated	 in	 X-
chromosome	 inactivation)	 has	 been	 known	 for	 some	 time	 [32,	 33],	 the	 full	 recognition	 for	









poor	 species	 conservation	 compared	 to	 protein	 coding	 genes.	 These	 characteristics	 have	
caused	skepticism	on	the	actual	functional	relevance	of	lncRNAs.	On	the	other	hand,	their	com-
plex	secondary	and	tertiary	structures	hint	towards	functional	active	molecules	[34,	35],	a	no-







pending	 on	 their	 transcriptional	 orientation	 compared	 to	 the	 protein-coding	 gene.	 ‘Intronic’	
lncRNAs	are	transcribed	from	an	intron	of	another	transcript,	whereas	‘intergenic’	lncRNAs	are	










transcribed	 at	 enhancers,	 the	 so-called	 eRNAs,	 has	 been	 described	 [43,	 44].	 Post-
transcriptionally,	 lncRNAs	have	been	detected	to	aid	mRNA	processing	and	direct	splicing	[45,	
46]	 and	 also	 effects	 on	 translation	 or	mRNA	degradation	 have	 been	 encountered	 21307942.	
Some	lncRNAs	also	have	several	binding	sites	for	a	miRNA.	These	lncRNAs	are	called	competi-
tive	 endogenous	 RNAs	 (ceRNAs)	 as	 they	 titrate	miRNAs	 away	 from	 their	 conventional	 target	
mRNA	[47-49].	(Review	on	lncRNA	functions	in	[50])	















In	the	 last	years,	 it	was	shown	that	a	key	subset	of	 lncRNAs	 is	expressed	from	enhancer	sites	
[54].	Enhancers	are	 loci	on	 the	genome	that	are	bound	by	specific	 factors	 that	modulate	 the	
transcriptional	activity	of	a	nearby	gene.	These	loci	are	demarcated	in	the	genome	by	specific	
histone	 modifications	 (e.g.	 H3K27ac	 and	 H3K4me1)	 and	 binding	 of	 key	 transcription	 factors	



















T-ALL	with	distinct	 gene	expression	patterns	 [70-74]:	 the	TAL-rearranged	 subgroup,	 the	TLX1	
subgroup,	 the	 TLX3	 subgroup	 and	 the	HOXA-overexpressing	 subgroup.	 Recently,	 a	 fifth	 sub-
group	with	a	poor	prognosis,	the	immature	T-ALL	subgroup,	has	been	added	with	an	early	T-cell	
progenitor	phenotype,	but	no	single	specific	oncogenic	driver	event.	This	subgroup	 is	marked	




ing	 that	 hyperactive	NOTCH1	 signaling	 plays	 a	 central	 role	 in	 T-ALL	 biology	 [75].	 The	NOTCH	













MiRNA	expression	 studies	 have	 initially	 used	RT-qPCR	or	microarray	platforms,	which	 enable	









sitions	 2-7	 from	 the	 5’-end	 that	 can	 interact	 through	 complementary	 basepairing	 with	 the	
3’UTR	of	 the	miRNA.	 For	 this,	 several	 online	 tools	 can	be	used,	 including	miRDB	 (mirDB.org)	
[89],	 miRanda	 (microRNA.org)	 [90],	 TargetScan	 (targetscan.org)	 [91]	 and	 the	 recently	 devel-
oped	miSTAR	(mi-star.org)	[92],	which	also	enable	the	identification	of	all	miRNAs	that	poten-









Target	 prediction	 can	 also	 be	 achieved	 through	 several	 in	 vitro	methods.	 High-troughput	 se-
quencing	 methods	 used	 for	 miRNA-mRNA	 interaction	 detection	 are	 for	 example	 HITS-CLIP	
(High-throughput	sequencing	of	RNA	isolated	by	crosslinking	immunoprecipitation)	[95]	or	PAR-





be	 identified	 [96-98].	 Next	 to	 these	 methods,	 all	 miRNA-mRNA	 interactions	 can	 be	 directly	
mapped	using	the	CLASH	(crosslinking,	 ligation	and	sequencing	of	hybrids)	technology	[93].	 In	









To	 validate	potential	miRNA-mRNA	 interactions,	 a	 luciferase	 reporter	 assay	 is	 the	method	of	
choice.	In	this	assay,	the	3’UTR	of	the	target	mRNA	is	cloned	next	to	a	reporter	gene	(e.g.	lucif-
erase)	 and	 a	 functional	miRNA-mRNA	 interaction	 should	 result	 in	 a	 decrease	of	 the	 reporter	
gene	 signal	 after	 overexpression	 of	 the	miRNA	 of	 interest.	 A	 direct	 interaction	 between	 the	
miRNA	and	the	3’UTR	of	 the	 target	gene	could	 then	be	confirmed	 if	 the	decrease	 in	signal	 is	
rescued	by	mutations	of	the	miRNA	binding	sites.		
This	reporter	assay	has	also	been	applied	in	3’UTR	library	screens	in	order	to	detect	possible	in-
teractions	of	 known	miRNAs	with	 a	 certain	 gene	of	 interest.	 In	 such	3’UTR	 library	 screens,	 a	
plasmid	containing	the	luciferase	report	gene	with	the	3’UTR	of	the	gene	of	interest	and	a	miR-
NA	library	are	transfected	together	in	HEK293T	cells	[99].	Subsequent	screening	of	the	lucifer-









are	 injected	by	 tail	 vein	 injection.	 The	 leukemia	 onset	 of	 these	mice,	 compared	with	 control	
mice	(ICN1	+	a	negative	control	miRNA),	gives	an	indication	of	the	oncogenic	or	tumor	suppres-
sive	potential	of	the	tested	miRNA.	
Junker	 et	 al.	 showed	 that	 the	 leukemia	 onset	 of	 this	mouse	model	 is	 dependent	 on	Dicer1-
mediated	biogenesis	of	miRNAs	[101].	When	HPCs	with	 ICN1	overexpression	were	 injected	 in	
conditional	Dicer1	 knock	out	mice,	where	Dicer1	 is	 inactivated	when	 thymocytes	or	 leukemic	






icant	 tissue	and	 spatial	 specific	 expression	of	 lncRNAs.	RNA-sequencing	detection	of	 lncRNAs	
requires	a	higher	read	depth	in	comparison	to	protein	coding	mRNAs,	given	the	low	expression	

















































promoter	 of	 lncRNAs	 showed	 a	 higher	 degree	 of	 sequence	 conservation	 than	 the	 exons	 and	
that	 this	 promoter	 conservation	was	 similar	 to	 the	 promoter	 conservation	 of	 protein	 coding	
genes	[104,	107,	115,	116].	This	topic	is	also	reviewed	by	I.	Ulitsky	[117].		One	way	to	study	the	
oncogenic	 potential	 of	 lncRNAs	 in	 vivo	 without	 the	 knowledge	 of	 the	 mouse	 orthologous	
lncRNA,	is	the	use	of	xenografts	by	implanting	human	cell	lines	in	mice.	These	cell	lines	could	be	









in	T-ALL	was	strongly	 suggested	 through	 the	 finding	of	a	new	translocation	 t(13;14)(q32;q11)	
that	juxtaposed	the	miR-17~92	cluster	to	the	TCRA/D	locus	thereby	placing	it	under	the	imme-




effectively	 contributed	 to	 T-ALL	 formation,	 cytokine	 dependent	 FL5-12	 lymphocytes	 were	
transduced	with	individual	miRNAs	of	the	cluster	followed	by	IL-3	withdrawal.	In	these	assays,	
miR-19b	showed	the	strongest	oncogenic	capacity,	which	 is	 in	 line	with	the	fact	that	miR-19b	
shows	 the	 highest	 expression	 of	 all	 members	 of	 the	miR-17~92	 cluster	 in	 human	 T-ALL.	 A	
NOTCH1-sensitized	mouse	model	was	subsequently	used	to	confirm	the	oncogenic	role	of	miR-
19b	 in	vivo.	Finally,	 target	prediction	algorithms	 in	combination	with	 functional	validation	ex-
periments	 identified	 different	 components	 of	 the	 PI(3)K	 signaling	 pathway	 as	 direct	miR-19b	
targets,	including		PP2A,	PRKAA1,	BIM	and	PTEN.		
A	 few	 years	 later,	 Ye	 et	 al.	 performed	 a	 large	 bio-informatics	 screening	 to	 point	 out	 central	
hubs	in	the	T-ALL	network	[120].	To	this	end,	combinations	of	genes	and	miRNAs	known	to	be	
involved	 in	 T-ALL	were	 tested	with	 target	 prediction	 algorithms.	 Furthermore,	 possible	 tran-














fication	 of	 a	 network	 of	 5	 oncogenic	miRNAs	 (miR-19b,	miR-20a,	miR-26a,	miR-92	 and	miR-
223),	which	shared	a	panel	of	direct	tumor	suppressor	target	genes	previously	implicated	in	T-
ALL	biology	(IKZF1,	PTEN,	BIM,	PHF6,	NF1	and	FBXW7).	MiRNAs	with	the	same	target	genes	also	
showed	 a	 cooperative	 effect	 on	 cell	 viability.	 Three	 of	 these	miRNAs	 (miR-19b,	miR-20a	 and	
miR-92)	belong	to	the	oncogenic	miR-17~92	cluster,	whereas	miR-223	was	subsequently	shown	
to	 be	 activated	 by	 TAL1	 [122,	 123]	 and	NOTCH1	 [124],	 two	 important	 T-ALL	 oncogenes	 (dis-
cussed	below),	further	supporting	the	original	observations	of	this	study.	
In	subsequent	studies,	additional	miRNAs	with	an	oncogenic	role	in	the	development	of	T-ALL	
















in	 T-ALL	patient	 samples	 to	detect	potential	 novel	 oncomiRs.	 For	 example,	 the	expression	of	




lation	[128].	miR-181a	 is	also	 linked	to	the	NOTCH1	signaling	pathway	which	 is	discussed	fur-
ther	in	more	detail	[129].	
3.3.2 T-ALL	tumor	suppressor	miRNA	






















patients,	 in	keeping	with	MYB	upregulation	 in	 this	T-ALL	genetic	 subtype.	 Importantly,	 inhibi-





















Furthermore,	miR-223	 has	 been	 linked	 to	 a	myeloid-like	 T-ALL	 phenotype[136],	 but	 has	 also	


















mouse	 model.	MiR-451	 and	miR-709	 directly	 target	 c-Myc,	 a	 known	 oncogene	 activated	 by	
NOTCH1	in	T-ALL.	Next	to	c-MYC,	miR-709	also	directly	targets	Ras-GRF1	and	Akt.	Motif	analysis	
followed	by	ChIP-sequencing	revealed	 the	positive	 regulation	of	 these	miRNAs	by	E2A,	which	
itself	 is	 inhibited	 by	NOTCH1	 signaling.	 The	NOTCH1/miR-451/c-MYC	 axis	 also	 plays	 a	 role	 in	
human	T-ALL	(miR-709	has	no	human	homologue)	[138].	
Later,	this	network	was	further	expanded	by	adding	a	feed	forward	loop	between	NOTCH1	and	






























specific	T-ALL	subtype.	Mansour	et	al.	 studied	the	downstream	miRNAs	of	TAL1	 [122].	 In	 this	
study	miR-223	 was	 the	 most	 promising	 candidate	 as	 it	 was	 most	 strongly	 differentially	 ex-




































ALL,	 TAL-R:	 TAL-rearranged	 T-ALL,	 IMM:	 Immature	 T-ALL,	 HOXA:	 HOXA-overexpressing	 T-ALL.	 The	 most	 recent	
miRBase	annotation	was	retrieved	using	the	miRBase	Tracker,	www.mirbasetracker.org	[143].	




miR-19b	 hsa-miR-19b-3p	 ONC	 BIM,	CYLD,	PP2A,	
PRKAA1,	PTEN	
[119-121]	
miR-20a	 hsa-miR-20a-5p	 ONC	 BIM,	PHF6,	PTEN	 [121]	
miR-21	 hsa-miR-21-5p	 ONC	 PDCD4	 [101]	
miR-26a	 hsa-miR-26a-5p	 ONC	 BIM,	PHF6,	PTEN	 [121]	






miR-31	 hsa-miR-31-5p	 TSG	 HBP1	 [130]	
miR-92	 hsa-miR-92a-3p	 ONC	 BIM,	 FBXW7,	
IKZF1,	NF1,	PTEN	
[121]	
miR-101	 hsa-miR-101-3p	 Targets	TAL1	 TAL1	 [142]	
miR-128-3p	 hsa-miR-128-3p	 ONC	 PHF6	 [99]	
miR-140-5p	 hsa-miR-140-5p	 Targets	TAL1	 TAL1	 [142]	
miR-142-3p	 hsa-miR-142-3p	 ONC	 cAMP,	GRα,	PKA	 [125]	
miR-146b-5p	 hsa-miR-146b-5p	 TAL1	repressed	 	 [123]	
miR-149*	 hsa-miR-149-3p	 ONC	 JunB	 [126]	
miR-150	 hsa-miR-150-5p	 TSG	 MYB	 [130]	
miR-155	 hsa-miR-155-5p	 TSG	 HBP1,	MYB	 [130]	








miR-200c	 hsa-miR-200c-3p	 TSG	 HBP1,	MYB	 [130]	
miR-204	 hsa-miR-204-5p	 TSG	 SOX4	 [132]	
miR-221	 hsa-miR-221-3p	 ETP	high	 	 [137]	








miR-363	 hsa-miR-363-3p	 ETP	low	 	 [137]	
miR-448	 hsa-miR-448	 Targets	TAL1	 TAL1	 [142]	
miR-451	 hsa-miR-451a	 NOTCH1	repressed	 c-MYC	 [138]	
miR-485-5p	 hsa-miR-485-5p	 Targets	TAL1	 TAL1	 [142]	
miR-520d-5p	 hsa-miR-520d-5p	 Targets	TAL1	 TAL1	 [142]	
miR-590	 hsa-miR-590-5p	 ONC	 RB1	 [127]	















The	 first	 comprehensive	 study	 of	 lncRNAs	 in	 T-ALL	 comprised	mRNA	 and	 lncRNA	 expression	
profiles	 of	 T-ALL	 cell	 lines	 and	 primary	 T-ALL	 patient	 samples	 by	means	 of	 deep	 total	 RNA-
sequencing.	Direct	NOTCH1-regulated	lncRNAs	were	determined	by	pharmacological	inhibition	
of	 the	NOTCH1	pathway	by	means	of	GSIs	 in	 two	T-ALL	cell	 lines	and	by	NOTCH/RBPJκ	ChIP-
sequencing.	Trimarchi	et	al.	prioritized	LUNAR1	(leukemia	induced	noncoding	activator	RNA	1)	




the	 transcript	 structure	 of	 LUNAR1,	 as	 determined	 by	 ‘Rapid	 Amplification	 of	 cDNA	 Ends’	































rection	 and	 is	 higher	 expressed	 in	 T-ALL	 patient	 bone	marrow	 compared	 to	 healthy	 control	





of	 64	 primary	 T-ALL	 patient	 samples	 for	 expression	 of	 all	 protein	 coding	 genes	 and	 13,000	
lncRNAs	 [145].	 This	 cohort	 consisted	 of	 15	 immature,	 17	 TLX1/3,	 25	 TAL-rearranged	 and	 7	
HOXA	overexpressing	T-ALL	cases.	This	 study	allowed	defining	subsets	of	 lncRNAs	specific	 for	
each	 of	 the	 T-ALL	 genetic	 subtypes.	 	 Furthermore,	 the	 authors	 linked	 the	 lncRNA	expression	
pattern	 in	 these	 T-ALL	 subtypes	 to	 the	 different	 stages	 of	 healthy	 T-cell	 development	 in	 the	
thymus.	As	the	immature	T-ALL	subtype	lymphoblasts	occur	from	a	differentiation	arrest	early	
during	T-cell	development	 (CD34+	 thymocytes),	 it	appeared	that	several	 lncRNAs	that	are	up-
regulated	 in	 the	 immature	T-ALL	 subtype	are	also	higher	expressed	 in	 the	CD34+	 thymocytes	
compared	to	later	stages	during	T-cell	development.	These	lncRNAs	might	be	involved	in	nor-
mal	 T-cell	 development.	 On	 the	 other	 hand,	 lncRNAs	were	 identified	 in	 the	 immature	 T-ALL	





Normal	thymopoiesis	 is	a	tightly	regulated	developmental	process	that	 is	 initiated	with	CD34+	
early	T-cell	progenitors	 that	migrate	 from	the	bone	marrow	 towards	 the	 thymus.	Within	 this	
thymic	microenvironment,	discrete	developmental	stages	of	T	cell	development	can	be	identi-
fied	through	a	combination	of	cell	surface	markers	(CD34,	CD4,	CD8,	CD3	etc.)	and	each	of	the-












for	miRNAs	 in	 the	double	negative	 to	double	positive	stage	 transition	 [146,	147].	 In	addition,	
miRNA	processing	by	Dicer	 is	also	necessary	 for	 the	positive	selection	of	 thymocytes	and	 the	








Furthermore,	 it	has	been	shown	that	miR-181a	 increases	 thymocyte	sensitivity	by	directly	 in-

















The	miR-17~92	 cluster	 inhibits	 the	expression	of	PTEN	 and	of	 the	pro-apoptotic	protein	BIM,	







forward	 loop,	 cell-to-cell	 variation	 in	 the	 thymocytes	 is	 regulated.	 This	 further	marks	 the	 im-
portance	of	miRNAs	during	normal	T-cell	development	[155].	(Figure	10)	
3.5.2 LncRNAs	in	T-cell	development	
As	 lncRNAs	 are	 known	 to	 be	 expressed	 tissue	 specifically,	 it	 should	 be	 no	 surprise	 that	 also	










like	 ligand	1)[61],	 leading	 to	 activation	of	NOTCH1	 signaling.	RNA-sequencing	was	performed	
after	48	hours	of	co-culture	and	showed	a	clear	shift	in	lncRNA	expression.	Furthermore,	ex	vivo	
purified	 human	 thymocyte	 subsets	 (CD34+CD1-CD4+,	 CD34+CD1+CD4+,	 CD4+CD8+CD3-	 and	
CD4+CD8+CD3+)	were	profiled	on	an	expression	array.	The	NOTCH-regulated	 lncRNAs	selected	
from	the	co-culture	experiment	clearly	followed	the	expression	pattern	of	DTX1,	a	protein	cod-






To	 elucidate	 the	 molecular	 mechanisms	 that	 control	 early	 hematopoietic	 lineage	 choices	 in	
human,	 Casero	 et	 al.	 performed	 RNA-sequencing	 on	 several	 stages	 of	 B-	 and	 T-cell	 develop-
ment	[158].	Also	here,	stage-specific	patterns	of	lncRNA	expression	were	identified	during	the	
different	stages	of	T-cell	development.	Remarkably,	cell-type	specific	 lncRNAs,	and	not	highly	








cells	 segregated	with	 the	CD34+	populations	 in	 the	bone	marrow	and	not	with	more	mature	
(CD34-)	thymic	progenitor	cells.	However,	lncRNAs	clearly	made	the	distinction	between	thymic	
cells	 and	 bone	marrow	 derived	 cells.	With	 these	 data,	 the	 authors	 could	 show	 that	 the	 cell	
type-specific	nature	of	lncRNA	expression	could	be	used	to	define	developmental	relationships.		
Despite	the	low	amount	of	studies	describing	the	role	of	miRNAs	and	lncRNAs	in	early	T-cell	de-









In	 T-ALL,	 the	 role	 for	miRNAs	 is	 already	 explored	 in	 depth.	One	 landmark	publication	by	 the	
Wendel	team	could	link	several	miRNAs	to	protein	coding	genes	with	a	known	tumor	suppres-










not	been	discovered.	 	This	 is	partly	due	to	the	lack	of	species	conservation	of	 lncRNAs,	which	
makes	it	difficult	to	study	them	in	mouse	models,	but	also	because	a	detailed	study	describing	
an	 in-depth	 and	 full	 transcriptome	of	 all	 discrete	 stages	of	 human	T	 cell	 development	 is	 still	
missing.	Another	obstacle	 is	 the	broad	range	of	possible	 functional	mechanisms	that	 lncRNAs	










targeting	these	tissue	specific	RNAs	could	then	result	 in	 less	off-target	effects	of	 the	therapy.	
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spective	 it	will	be	crucial	 to	 further	unravel	 the	molecular	basis	of	T-ALL	biology	and	 identify	
novel	targets	for	development	of	 innovative	therapy	protocols.	Technological	advances	 in	the	
field	have	opened	new	possibilities	to	dissect	the	T-ALL	transcriptome	and	recent	findings	un-
derscore	 the	 importance	of	noncoding	RNA	molecules,	 such	as	miRNAs	and	 lncRNAs,	next	 to	
protein	coding	genes	in	various	cancer	entities	and	also	T-ALL.		











































the	 lncRNA	 profiles	 that	 can	 differentiate	 the	 distinct	 T-ALL	 subtypes	 and	 I	 could	 show	 that	
RNA-sequencing	is	indeed	a	better	option	for	lncRNA	profiling	as	compared	to	micro-arrays,	as	




In	 the	 last	decade,	 several	miRNAs	have	been	 linked	 to	T-ALL	development.	These	are	either	
oncogenic	miRNAs	or	tumor	suppressive	miRNAs	that	target	respectively	known	tumorsuppres-
sor	 genes	 or	 oncogenes	 in	 T-ALL.	 These	 studies	made	 use	 of	 an	 RT-qPCR	 platform	 to	 detect	
miRNA	expression	levels	in	primary	T-ALL	cases,	but	could	never	define	a	subtype	specific	miR-
NA	signature.	We	therefore	measured	miRNA	expression	levels	in	48	T-ALL	patient	samples	of	












































































































to	 establish	 a	 comprehensive	 compendium	of	 the	 long	non-coding	RNA	 transcriptome	under	
control	of	Notch	 signaling.	 For	 this	purpose,	we	measured	 the	 transcriptional	 response	of	 all	
protein	coding	genes	and	long	non-coding	RNAs	upon	pharmacological	Notch	inhibition	in	the	
human	 T-cell	 acute	 lymphoblastic	 leukemia	 cell	 line	 CUTLL1	 using	 RNA-sequencing.	 Similar	
Notch	dependent	profiles	were	established	for	normal	human	CD34+	thymic	T-cell	progenitors	
exposed	to	Notch	signaling	activity	in	vivo.	In	addition,	we	generated	long	non-coding	RNA	ex-
pression	 profiles	 (array	 data)	 from	 ex	 vivo	 isolated	 Notch	 active	 CD34+	 and	 Notch	 inactive	
CD4+CD8+	thymocytes	and	from	a	primary	cohort	of	15	T-cell	acute	lymphoblastic	leukemia	pa-
tients	with	known	NOTCH1	mutation	status.	Integration	of	these	expression	datasets	with	pu-






The	 Notch	 pathway	 comprises	 a	 highly	 con-
served	 signaling	 pathway	 that	 regulates	 va-
rious	 cellular	 processes	 in	 all	metazoans,	 in-
cluding	 stem	cell	maintenance,	 regulation	of	
cell	 fate	 decisions,	 cellular	 proliferation,	 dif-
ferentiation,	 cell	 death	 and	 adult	 tissue	 ho-






tion	 of	 the	 various	 developmental	 cues	 and	
cellular	processes.	Consequently,	constitutive	
or	 acquired	 perturbation	 of	 Notch	 signaling	
frequently	 leads	 to	 human	 disease	 and	 can-
cer.1-4	
Notch	signaling	plays	multiple	roles	in	hema-
topoiesis	 and	 is	 essential	 for	 the	 establish-
ment	of	definitive	hematopoiesis	through	the	
generation	 of	 hematopoietic	 stem	 cells,5	 as	
well	as	for	their	subsequent	differentiation	in	






Subsequently,	 Notch	 signaling	 is	 imple-
mented	 in	 TCR-rearrangements,15,16	modula-
tion	 of	 TCR-αb	 versus	 –γδ	 development,17-21	
and	 in	 the	 support	of	proliferation	during	β-
selection.22-24		Sustained	activation	of	Notch1	
signaling	 beyond	 this	 developmental	 check-
point	 has	 been	 shown	 to	 cause	 T-cell	 acute	





activating	 mutations	 are	 amongst	 the	 most	
frequently	observed	genetic	 alterations	 in	 T-
ALL.25,26	 Importantly,	 γ-secretase	 inhibitors	
(GSIs)	 that	 block	 S3	 cleavage	 of	 the	 Notch1	
receptor	and	subsequent	release	of	the	intra-
cellular	signaling	domain	(ICN)	are	the	subject	
of	 intensive	 investigation	 as	 novel	 drugs	 to	
combat	 T-ALL.	 However,	 single	 compound	
therapies	almost	invariably	lead	to	resistance.	
Therefore,	 a	 deeper	 understanding	 of	Notch	
signaling	 in	 normal	 thymocyte	 maturation27	
and	 in	 Notch1	 activated	 T-ALLs	 could	 yield	
novel	 insights	 that	 could	 make	 treatment	
more	effective.		
Activation	of	Notch1	 converts	 the	 intracellu-
lar	domain	(ICN1)	of	the	Notch1	receptor	into	
a	 transcriptional	 activator	 and	 ICN1	 subse-
quently	acts	as	a	direct	regulator	of	multiple	
target	 genes.28	 However,	 despite	 intensive	
investigation,	 the	 nature	 of	 these	 genes,	 as	
well	 as	 their	 context-dependent	 activation,	
remains	largely	elusive.	In	general,	oncogenic	
Notch	 signaling	 promotes	 leukemic	 T-cell	
growth	through	direct	transcriptional	upregu-
lation	of	multiple	 anabolic	 genes	 involved	 in	
ribosome	 biosynthesis,	 protein	 translation,	
and	 nucleotide	 and	 amino	 acid	 metabolism.	
Furthermore,	 Notch1	 positively	 regulates	
G1/S	 cell	 cycle	 progression	 in	 T-ALL29-31	 and	
up-regulates	 several	 cyclins	 and	 CDKs,30	 	 in	
addition	to	the	recurrent	oncogene	MYC.	
Furthermore,	 Notch	 signaling	 regulates	 cell	
size,	 glucose	 uptake	 and	 PI3K-AKT	 activated	
glycolysis	 through	 HES1-mediated	 PTEN	 re-
pression.	 Besides	 direct	 regulation	 of	 HES1,	
Notch1	is	also	implicated	in	the	control	of	es-
sential	 early	 T-cell	 genes	 such	 as	 pre-TCRα	
(PTCRA)	 and	 IL7R.32-34	 Taken	 together,	 these	
genes	and	pathways,	as	well	as	a	 further	ex-
panding	 list	 controlled	 by	 Notch1	 in	 T-ALL	
and	normal	T-cell	development,	illustrate	the	
complexity	 and	 vastness	 of	 the	 Notch1	 con-
trolled	regulatory	program.  
Recent	 transcriptome-wide	 profiling	 efforts	
have	 uncovered	 an	 unanticipated	 pervasive-
ness	 of	 transcription	 of	 the	 human	 genome,	
most	 of	 which	 is	 not	 translated	 into	 pro-
tein.35-38	Evidence	is	now	emerging	that	more	
than	 60%	 of	 the	 entire	 genome	 is	 transcri-
bed.39	 In	 addition	 to	 previously	 well-
characterized	 untranslated	 RNA	 molecules	
such	 as	 tRNAs,	 snoRNAs	 and	 microRNAs	





portant	 cellular	 functions	 are	 rapidly	 being	
attributed	to	some	of	them,	including	roles	in	
disease	 processes	 such	 as	 cancer.42	 In	 con-
trast	 to	microRNAs,	 a	 picture	 is	 emerging	 in	
which	 lncRNAs	can	exhibit	a	myriad	of	diffe-
rent	 functions.	 These	 include	various	 regula-
tory	 mechanisms	 of	 gene	 transcription,	
splicing,	 post-transcriptional	 control,	 protein	
activity	and	nuclear	architecture.43-45	Despite	
this	initial	progress,	mechanisms	of	upstream	
regulation	 of	 lncRNAs	 have	 so	 far	 remained	
largely	unexplored.		
In	this	study,	we	investigate	the	role	of	Notch	
in	 the	 control	 of	 lncRNA	 transcription	 in	 the	
context	of	normal	T-cell	development	and	T-
ALL.	To	this	end,	lncRNA	expression	was	mea-
sured	 following	 modulation	 of	 Notch	 signa-
ling	in	the	T-ALL	cell	line	CUTLL1	as	well	as	in	
normal	human	 thymocytes,	and	 the	 recently	
published	data	on	genome-wide	Notch1	bin-
ding	sites	was	used	to	reveal	the	potential	for	










HPB-ALL,	 TALL-1,	 ALL-SIL	 and	 CUTLL1	 cells	
(see	 also	 Online	 Supplementary	 Methods)	
were	 seeded	 at	 a	 density	 of	 1x106	 cells/mL	
and	 treated	 with	 either	 DMSO	 or	 1	 μM	 of	
Compound	E	 (Enzo	Life	Sciences).	Cells	were	
harvested	12	and	48	h	after	treatment.	







(MACS,	Miltenyi	 Biotec)	 to	 a	 purity	 of	more	
than	 98%	 and	 seeded	 onto	 confluent	 OP9-
GFP	 or	 OP9-DLL1	 plates	 for	 48	 h	 in	 α-MEM	
media	 supplemented	 with	 20%	 heat-
inactivated	FCS	plus	100	U/mL	penicillin,	100	
μg/mL	 streptomycin,	 2	mM	 L-glutamine	 and	
the	T-lineage	supporting	cytokines	SCF,	Flt3-L	
and	IL-7	at	5	ng/mL	each.20	Following	48	h	of	
OP9	 co-culture,	 cells	were	 harvested	 by	 for-
ceful	 pipetting	 and	 stained	 with	 CD45-PE	
(Miltenyi)	to	purify	CD45+	human	thymocytes	
through	 sorting	 to	 remove	 contaminating	
OP9	 stromal	 cells.	 For	 validation	 of	 selected	
lncRNAs,	 CD34	 MACS	 purified	 thymocytes	
were	labeled	with	CD34,	CD1	and	CD4	to	sort	
CD34+CD1–CD4–	 uncommitted	 and	
CD34+CD1+	 CD4–	 committed	 early	 thymo-
cytes,	 while	 CD4+	 CD8+CD3–	 and	
CD4+CD8+CD3+	 double	 positive	 thymocytes	





Diagnostic	 blood	 samples	 of	 15	 individuals	
with	T-ALL	were	acquired	after	informed	con-
sent	from	the	Department	of	Pediatric	Hema-
to-Oncology	 at	 Ghent	 University	 Hospital,	
Belgium.	 This	 cohort	 includes	 8	 wild-type	
NOTCH1	 cases	 and	 7	mutant	NOTCH1	 cases	
(all	 FBXW7	 wild	 type).	 Sequencing	 was	 per-
formed	as	described	by	Mavrakis	et	al.46	Cor-
relation	 analysis	 was	 performed	 on	 bone	





was	 approved	 by	 the	 Institut	 Universitaire	
d’Hématologie	 Institutional	 Review	 Board.	
This	 primary	 T-ALL	 cohort	 had	 been	 previ-
ously	investigated47	and	the	high-quality	RNA	
samples	 from	 this	 cohort	 were	 used	 for	
lncRNA	 micro-array	 based	 expression	 profi-
ling.		
RNA	sequencing	
RNA	 samples	 from	 the	 CUTLL1	 cells	 treated	
with	 GSI	 and	 thymocytes	 cultured	 on	 OP9-
GFP/DLL1	 were	 prepared	 (see	 also	 Online	
Supplementary	 Methods).	 RNA-seq	 was	 per-
formed	 after	 unstranded	 poly-A	 library	 prep	
with	an	average	coverage	of	130x106	paired-
end	 reads.	 Reads	were	mapped	 to	 the	 hg19	
reference	 genome	 using	 Tophat	 and	 trans-
cript	assembly	was	performed	with	Cufflinks.	
Normalizaton	and	differential	expression	ana-










ned	 Agilent	 micro-array	 covering	 all	 protein	
coding	 genes	 and	 12,000	 lncRNAs	 (23,042	
unique	 lncRNA	 probes)	 as	 described	 by	 Vol-
ders	 et	 al.48	 The	 data-analysis	 workflow	 can	
be	 found	 in	 the	 Online	 Supplementary	 Me-
thods.	 The	data	discussed	 in	 this	publication	
have	 been	 deposited	 in	 the	 NCBI	 Gene	 Ex-
pression	 Omnibus49	 and	 are	 accessible	
through	 GEO	 Series	 accession	 number	





Pharmacological	 Notch	 inhibition	 followed	
by	 RNA-sequencing	 reveals	 a	 set	 of	 Notch	
regulated	lncRNAs	in	T-ALL.	
To	 identify	 lncRNAs	 that	 are	 regulated	
through	 Notch	 signaling	 activity	 in	 the	 con-
text	 of	 T-ALL,	 we	 used	 the	 γ-secretase	 (GSI)	












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































to	 Notch1	 binding34	 and	 the	 Notch	 depen-
dent	expression	of	coding	genes.50	CUTLL1	T-
ALL	 cells	were	 treated	with	 GSI	 for	 12h	 and	
48h	 in	 triplicate.	 Genome-wide	 transcriptio-
nal	changes	determined	by	performing	diffe-
rential	 expression	 analysis	 on	 the	 RNA-seq	
data	 (see	alignment	 summary	 in	Online	Sup-
plementary	 Table	 S1)	with	DESeq2	using	 En-
sembl	 (release	 75)	 as	 a	 reference,	 showed	
robust	 downregulation	 of	 several	 of	 the	 ca-
nonical	 Notch1	 protein	 coding	 target	 genes	
(e.g.	DTX1,	NRARP,	NOTCH3)	upon	GSI	treat-
ment	(Figure	1A).	A	decrease	in	ICN1	protein	
levels	 was	 shown	 by	 Western	 blot	 analysis	
and	downregulation	of	 the	canonical	Notch1	
target	 gene	 DTX1	 upon	 GSI	 treatment	 was	
further	 validated	 by	 RT-qPCR	 (Online	 Sup-





83	 differentially	 expressed	 lncRNAs	 were	
downregulated	 after	 GSI	 treatment.	 Besides	
previously	annotated	lncRNAs,	we	also	detec-
ted	 differential	 expression	 of	 non-coding	
transcripts	 that	 had	 not	 been	 previously	 an-
notated	 in	 other	 databases	 (Gencode,	 lncR-
NAdb,	 Broad	 Institute	 and	 Ensembl	 release	
64).48	 Differentially	 expressed	 lncRNA	 loci	
with	a	basemean	higher	than	100	and	identi-
fied	 as	 “unknown,	 intergenic	 transcript”	 or	
“transfrag	 falling	 entirely	 within	 a	 reference	




Transcriptional	 regulation	 of	 Notch	 regula-









dependent	 lncRNAs,	 we	 used	 the	 in	 vitro	
OP9-DLL1	 co-culture	 system	 (Figure	 2A).	He-
re,	 ex	 vivo	 purified	 CD34+	 thymocytes	 from	




CD34+	 progenitor	 cells	 were	 collected	 after	
48h	 of	 co-culture	 and	 deep	 RNA-sequencing	
was	 performed	 (see	 alignment	 summary	 in	
Online	 Supplementary	 Table	 S2).	 The	 set	 of	
differentially	expressed	protein	coding	genes	
and	 lncRNAs	 was	 defined	 as	 above	 for	 the	
CUTLL1	 cells.	 Detection	 of	 differentially	 ex-
pressed	 protein	 coding	 genes	 known	 to	 be	
regulated	by	Notch	 signaling	 in	 early	 human	
thymocytes,20,27	 also	 validated	 our	 approach	
in	this	model	system	(Figure	2B).	Differential	
expression	 analysis	 for	 previously	 annotated	
lncRNAs	 revealed	 131	 significantly	 upregula-
ted	lncRNAs	as	a	consequence	of	Notch	acti-
vation	 (Figure	 2C).	 From	 these	 131	 lncRNAs,	
27	overlapped	with	the	set	of	downregulated	
lncRNAs	 upon	 GSI	 treatment	 of	 the	 CUTLL1	
cell	line	(Figure	2D	and	Online	Supplementary	
Table	 S3).	 Furthermore,	 we	 identified	 156	
unannotated	 lncRNA	 loci	 (base	 mean	 >100;	
adjusted	P-value	<0.05)	 in	CD34+	thymocytes	








Figure	 2.	 Transcriptional	 regulation	 of	Notch	 regulated	 lncRNAs	 in	 immature	 normal	 human	 thymocytes.	 (A)	
Schematic	overview	of	the	OP9-control	and	-DLL1	co-culture	system	used	to	manipulate	Notch	signaling	in	healthy	














development	 (Figure	 2E	 and	 Online	 Supple-
mentary	 Table	 S4).	 Amongst	 the	 set	 of	 13	
overlapping	 Notch	 lncRNA	 loci,	 the	 recently	
described	 LUNAR151	 was	 present,	 thus	 sup-
porting	the	validity	of	our	approach.	 In	addi-
tion,	we	also	identified	33	annotated	lncRNAs	
to	 be	 up-regulated	 upon	 GSI	 treatment	 of	






viously	 unannotated	 lncRNAs	 upregulated	
upon	GSI	 treatment	of	CUTLL1	 cells	overlap-
ped	with	the	set	of	320	unannotated	lncRNAs	
downregulated	 in	 CD34+	 thymocytes	 with	
DLL1	 exposure	 (Online	 Supplementary	 Table	
S6	 and	 Figure	 S2B).	 Furthermore,	 we	 hypo-
thesize	 that	 the	 Notch	 dependent	 lncRNAs	
(both	 annotated	 and	 unannotated)	 that	 are	
not	 shared	 between	 CUTLL1	 T-ALL	 cells	 and	
normal	 human	 thymocytes	 can	 be	 assumed	
to	 have	 very	 context-specific	 functions	 and	
should	be	regarded	as	potentially	 interesting	
for	 further	 exploration	 in	 future	 studies.	 For	
example,	 lncRNAs	expressed	exclusively	 in	T-
ALL	cells	could	be	restrictively	connected	to	a	
malignant	 context.	 To	 evaluate	 the	 putative	
protein	 coding	 potential	 of	 all	 unannotated	
lncRNA	 loci	 identified	 by	 RNA-seq	 in	 CUTLL1	




firm	 that	more	 than	90%	of	 all	 unannotated	
lncRNA	loci	determined	are	truly	‘non-coding’	
(Online	 Supplementary	 Figure	 S3).	 Putative	
unannotated	 lncRNA	 loci	 with	 a	 PhyloCSF	
score	 higher	 than	 the	 determined	 threshold	
score	are	listed	and	thus	predicted	to	be	‘co-











described	 RNA-seq	 data	 from	 the	 T-ALL	 and	
normal	 thymocyte	models.	 First,	 we	 treated	
the	 T-ALL	 cell	 lines	 ALL-SIL,	 TALL-1,	 HPB-ALL	
and	DND-41	with	GSI	 (Supplementary	 Figure	
S4A	 and	 B)	 and	 carried	 out	 gene	 expression	
profiling	after	12	h	and	48	h.	Inclusion	of	the	
GSI-treated	CUTLL1	cell	 line	samples	and	the	
samples	 of	 4	 donors	 of	 CD34+	 thymocytes	
cultured	 on	OP9	 stromal	 cells,	 revealed	 that	
there	was	 a	 significant	 overlap	 between	 the	
RNA-sequencing	data	and	the	micro-array	da-
ta	 as	 validated	 by	 overlapping	 the	 protein-
coding	signatures	derived	from	both	datasets	
by	 Gene	 Set	 Enrichment	 Analysis	 (GSEA)	
(Supplementary	 Figure	 S4C	 and	 D).	 Nevert-
heless,	 few	 lncRNAs	were	significantly	Notch	
dependent	over	 all	 samples	of	 the	extended	




of	 the	 different	 cell	 lines	 evaluated	 (Figure	
3A).	 From	 our	 selection,	 only	 lnc-PLEKHB2-1	
and	 lnc-UBXN4-1	 were	 differentially	 expres-
sed	at	 a	 significant	 level,	while	 lnc-GSDMC-2	
and	lnc-CA7-2	narrowly	failed	to	reach	signifi-
cance.	 As	we	were	 able	 to	 detect	 the	 previ-
ously	 unannotated	 and	 recently	 described	






the	 strongest	 overlapping	 and	 significantly	
differentially	expressed	lncRNAs	amongst	the	
four	GSI-treated	T-ALL	cell	lines	screened.	Se-
condly,	 we	 validated	 the	 Notch	 dependency	
of	selected	lncRNAs	in	normal	thymocytes	by	
analyzing	their	expression	in	the	most	imma-
ture	Notch	 dependent	 CD34+	 stages	 in	 com-
parison	 to	 the	Notch	 independent	CD4+CD8+	
double	positive	stages	of	human	T-cell	deve-
lopment.	 As	 is	 evident	 from	 the	 profiles	 of	
the	Notch	 target	gene	DTX1,	we	could	 show	
that	 in	 these	 two	 T-cell	 subpopulations	 LU-
NAR1	 follows	 the	 expression	 pattern	 of	 this	
canonical	 Notch	 target	 (Figure	 3B).	 Re-
markably,	9	out	of	15	lncRNAs	(and	LUNAR1)	
from	 this	 selection	 significantly	 correlated	
with	DTX1	expression	(Spearman	rho	correla-
tion),	 supporting	 their	 regulation	 by	 Notch	
during	early	stages	of	normal	T-cell	develop-




NOTCH1	 mutations	 while	 8	 were	 wild	 type	
(all	cases	are	FBXW7	wild	type).	There	was	a	
significant	 difference	 in	 expression	 of	 LU-
NAR1	 and	 lnc-FAM120AOS-1	 between	




relate	 the	 expression	of	 lncRNAs	 lnc-PGBD5-
2,	 lnc-FAM120AOS-1,	 lnc-c2orf55-1	 and	 LU-
NAR1	 with	 the	 Notch1	 positively	 regulated	
gene	 set	 Vilimas_NOTCH1	 _targets_up52	 by	
GSEA	(Figure	3E).	Overall,	these	independent	
experiments	 confirm	 the	 Notch	 dependent	
regulation	 of	 the	 selected	 lncRNAs,	 thereby	






lected	 lncRNAs	 by	 Notch,	 publicly	 available	
ChIP	 sequencing	 (ChIP-seq)	 data	 from	 the	
CUTLL1	 cell	 line	 were	 analyzed	 for	 Notch1	
binding	 at	 specific	 loci.34	 From	 the	 Notch-
driven	 annotated	 lncRNAs	 that	 overlapped	
between	 normal	 and	 malignant	 thymocytes	
(Figure	 2D),	 13	 out	 of	 the	 27	 lncRNAs	 were	
bound	by	 ICN1	 (Online	Supplementary	Table	
S12)	 as	 illustrated	 for	 lnc-UBXN4-1	 and	 lnc-
PLEKHB2-1	 (Figure	4).	Remarkably,	12	out	of	
the	 13	 lncRNAs	 with	 a	 Notch1	 binding	 peak	
also	 show	 Brd4	 and	Med1	 binding.	 Notably,	




S5)	 showed	binding	 of	 ICN1,	 suggesting	 that	
the	majority	is	a	direct	Notch	target.	
In	 addition,	 we	 evaluated	 the	 presence	 of	
H3K27	 acetylation	 (H3K27ac)	 ChIP-seq	 signal	
at	these	lncRNA	loci,	a	histone	mark	indicati-
ve	 for	putative	enhancer	 regions.	For	18	out	
of	 the	 27	 selected	 lncRNAs,	 H3K27ac	 ChIP-
seq	 signal	 was	 present	 in	 close	 proximity	 of	
the	 promoter	 region	 (Online	 Supplementary	
Table	 S12),	 suggesting	 the	 presence	 of	 en-
hancer	sequences.		
Moreover,	 this	 public	 ChIP-seq	 data	 also	
showed	 LUNAR1	 to	 be	 directly	 bound	 by	
ICN1,	 Brd4,	 Med1	 and	 H3K27ac	 (Figure	 5).	
We	also	evaluated	ICN1	binding	at	annotated	
lncRNA	loci	up-regulated	upon	GSI	treatment	
of	 CUTLL1	 T-ALL	 cells	 and	 downregulated	 in	
CD34+	T-cell	progenitors	upon	DLL1	exposure	


























plementary	 Figure	 S2A)	 showed	 direct	 bin-
ding	by	 ICN1.	 The	 same	analysis	was	perfor-
med	on	the	set	of	7	unannotated	lncRNAs	re-
pressed	 by	Notch1	 signaling	 (Supplementary	
Figure	S2B).	Only	3	out	of	these	7	lncRNA	loci	
showed	 ICN1	 binding	 in	 the	 proximity	 of	 its	
promoter	 region.	 Given	 the	 established	 pre-
dominant	 role	of	Notch1	as	a	 transcriptional	
activator,	 lncRNAs	 that	 are	 negatively	 affec-
ted	by	Notch1	signaling	may	actually	be	indi-
rect	targets.	
Attributing	 functional	 annotation	 to	 Notch	
regulated	 lncRNAs	 through	 guilt-by-
association	analysis	
As	described	above,	we	defined	a	core	set	of	
27	 Notch	 driven	 and	 previously	 annotated	
lncRNAs	by	considering	only	those	differenti-
ally	 expressed	 and	 positively	 regulated	 by	
Notch	signaling	in	the	GSI	perturbation	model	
in	CUTLL1	cells	and	the	 in	vitro	OP9-DLL1	co-
culture	 system.	As	 a	next	 step,	we	aimed	 to	
assign	 potential	 functionalities	 to	 each	 of	
these	candidates.	To	this	end,	we	used	the	so	
called	 ‘guilt-by-association’	 approach	 (see	




form.	 In	 a	 first	 step,	 we	 calculated	 the	 Spe-
arman	 correlation	 coefficients	 between	 the	
lncRNAs-of-interest	 and	 all	 protein	 coding	
genes	using	the	expression	data	of	a	primary	
T-ALL	 cohort	 of	 64	 patients	 from	 which	 we	
profiled	 all	 samples	 on	 the	 custom	designed	
Agilent	array.48	These	correlations	were	sub-
sequently	 used	 as	 an	 input	 for	 a	 GSEA	 pre-
ranked	analysis.	Next,	the	output	of	this	GSEA	
analysis	 was	 further	 refined	 into	 functional	
clusters	of	enriched	gene	sets	using	the	Cyto-
scape	plug-in	enrichment	mapping.	This	ana-
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analyzed	 (including	 LUNAR1).	 Important	 pu-
tative	 functionalities	 were	 represented	 in	
each	of	 the	networks	as	exemplified	by	TCR-
signaling	 and	 phospholipid	 metabolism	 for	
lnc-PLEKHB2-1,	 DNA	 replication	 and	DNA	 re-
pair	for	 lnc-UBXN4-1	and	splicing	and	cell	cy-




players	 in	 normal	 development	 and	 disease,	
including	 cancer.	 In	 previous	 studies,	 we	 in-
vestigated	the	role	of	miRNAs	 in	T-cell	acute	
lymphoblastic	 leukemia	 (T-ALL),	 thereby	
identifying	a	small	 set	of	miRNAs	that	 is	 res-




tumor	 suppressor	 genes	 including	 IKZF1,	
PTEN,	BIM,	PHF6,	NF1	and	FBXW7,	and	more	
recently	 this	 network	 was	 expanded	 further	
with	PHF6.53	In	order	to	provide	some	insight	
into	 the	 genetic	 components	 driving	 long	
non-coding	RNAs	in	T-ALL	formation,	we	per-
formed	an	integrated	analysis	of	lncRNA	pro-
filing	 data	 sets	 from	 GSI	 inhibited	 Notch-
driven	 T-ALL	 cell	 lines	 and	 Notch-stimulated	
immature	 normal	 human	 thymocytes	 using	
the	OP9	co-culture	system,	together	with	pu-
blicly	available	genome-wide	data	on	Notch1	
binding	and	 specific	 chromatin	marks.	 In	ad-
dition,	 we	 correlated	 the	 expression	 of	
Notch-dependent	 lncRNAs	 with	 the	 Notch-
dependent	 stages	 of	 normal	 thymocytes	





new	 insights	 into	 Notch-dependent	 regula-
tion	 of	 lncRNAs	 in	 TALL	 and	 normal	 develo-
ping	 thymocytes.	 First,	 we	 unambiguously	
demonstrate	 that	 a	 significant	 number	 of	











Figure	 5.	 Notch1	 ChIP-seq	 reveals	 direct	 binding	 of	 Notch1	 to	 LUNAR1.	 LUNAR151	 (lnc-IGF1R-1)	 was	 identified	
amongst	 the	 top	 differentially	 expressed	 novel,	 unannotated	 lncRNAs	 in	 both	GSI-treated	 CUTLL1	 cells	 and	 CD34+	



















T	 lymphocytes	 (annotated	 as	 well	 as	 previ-
ously	 unannotated	 lncRNAs),	 supporting	 an	
important	 role	 for	 these	 lncRNAs	 in	 Notch-
regulated	T-cell	biology.	This	could	be	related	
to	various	functions	of	Notch	signaling,	inclu-
ding	T-cell	 lineage	 specification	and	 commit-
ment,	 proliferation	 and	 differentiation.	 Im-
portantly,	 the	 recently	 identified	 lncRNA	LU-
NAR151	 was	 present	 amongst	 the	 most	 ro-
bustly	Notch	regulated	long	non-coding	RNAs	
in	 our	 data	 sets.	 LUNAR1	 was	 shown	 to	 be	
required	 for	efficient	T-ALL	growth	as	a	 con-
sequence	 of	 its	 role	 in	 enhancing	 IGF1R	
mRNA	expression	 to	sustain	 IGF1	signaling.51	
As	a	prelude	to	assigning	functional	annotati-
on	 to	 the	 newly	 assigned	 Notch-regulated	
lncRNAs	 in	 this	 study,	 we	 applied	 the	 so-
called	 ‘guilt-by-association’	 approach	 in	
which	 functions	 are	 predicted	 based	 upon	
correlation	with	known	protein	coding	genes	
and	 subsequent	 gene	 set	 enrichment	 analy-
sis.	 For	 the	 selected	 lncRNAs,	 various	 func-
tions	 were	 predicted,	 several	 of	 which	 are	
linked	 to	T-cell	biology	or	processes	 that	are	
perturbed	 in	 cancer.	 This	 marks	 these	
lncRNAs	as	prime	targets	 for	 further	 functio-
nal	studies	 in	order	to	unravel	their	mode	of	
action	and	assess	 to	what	extent	 they	might	
serve	as	 future	 therapeutic	 targets	 for	 treat-
ment	of	T-ALL.	
Not	 all	 of	 the	 40	 overlapping	 lncRNAs	 dis-
played	 ICN1	 binding,	 as	 is	 evident	 from	 the	
publicly	 available	 ChIP-seq	 data.34	 This	 may	
relate	to	the	complexity	of	the	chromosomal	
3D-structures	 that	 are	 generated	 when	
lncRNAs	 act	 as	 cis-regulatory	 elements,	 as	




lncRNAs	 that	 are	 characterized	 by	 Brd4	 and	




A	 second	 aspect	 of	 our	 study	 involved	 the	
identification	 of	 novel,	 previously	 unannota-






ation,	 as	 well	 as	 restriction	 to	 very	 specific	
cell	 subsets.	 Typically,	 these	 lncRNAs	are	ex-
pressed	 at	 significant	 levels	 in	 these	 cells	
whereas	in	other	cell	types	their	expression	is	
very	low	or	absent.	Here,	we	identified	novel	
lncRNAs	 in	 the	 CUTLL1	 cell	 line	 and	 in	 the	
OP9-DLL1	co-culture	system.	Interestingly,	61	








are	 exposed	 in	 the	OP9-DLL1	 co-culture	 sys-
tem,	 can	 activate	 both	 Notch1	 and	 Notch3	
(Waegemans	E,	Van	de	Walle	I	and	Taghon	T,	
unpublished	 data	 on	 preferential	 Notch	 re-
ceptor-ligand	 interactions	 in	 human,	 2011)	
while	both	receptors	are	implicated	in	modu-
lating	human	T-cell	development.21	Both	sub-
sets	of	 lncRNAs	may,	 therefore,	 serve	as	no-
vel	therapeutic	targets	for	T-ALL	treatment.	It	
is	evident	that	our	work,	as	well	as	the	recent	
paper	 by	 Aifantis	 and	 colleagues,51	 strongly	
favors	 an	 important	 role	 for	 lncRNAs	 in	nor-
mal	T-cell	development	and	T-ALL	oncogene-
sis.	 Moreover,	 we	 show	 that	 the	 Notch1	





transcription	 of	 many	 of	 these	 long	 non-
coding	RNAs.	Therefore,	one	can	predict	that	
other	oncogenic	transcription	factors	and	dri-
vers	 in	 T-ALL,	 such	 as	 TAL1,	 TLX1/TLX3,	
LMO1/2	 and	 HOXA	 genes,	 as	 well	 as	 other	
transcriptional	regulators	of	normal	T-cell	de-
velopment,	 will	 also	 perform	 similar	
transcriptional	 control.	 Therefore,	 specific	 T-
ALL	 subgroups	 and	 more	 distinct	 subsets	 of	
normal	 immature	developing	T	 cells	need	 to	
be	 analyzed	 in	 human	 for	 detection	 of	 all	
lncRNAs.	 We	 predict	 that	 this	 will	 further	
dramatically	 expand	 the	 lncRNA	 landscape	
for	 T-ALL	 and	 thymocyte	 maturation,	 and	
thus	provide	an	 important	 regulatory	 frame-
work	 for	 understanding	 some	 of	 the	 unique	
features	 that	 control	 human	T-cell	 biology.27	
Finally,	 given	 the	 central	 role	 of	 oncogenic	
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HPB-ALL,	 TALL-1	 and	ALL-SIL	 cells	were	 obtained	 from	 the	DSMZ	 cell	 line	 repository,	 CUTLL1	
cells	were	a	kind	gift	of	H.G.	Wendel	(Memorial	Sloan	Kettering	Cancer	Center,	New	York,	USA).	
Cells	were	maintained	 in	RPMI-.-1640	medium	 (Life	Technologies,	52400-025),	 supplemented	
with	 10%	 or	 20	 %	 (ALL-SIL	 and	 CUTLL1)	 fetal	 bovine	 serum	 (Biochrom	 AG,	 S0615),	 1	 %	 L-
glutamin	 (Life	 Technologies,	 1514-148)	 and	 1%	 penicillin/streptomycin	 (Life	 Technologies,	
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We	used	 PhyloCSF	 to	 identify	 putative	 protein	 coding	 	 transcripts	 in	 the	 unannotated,	 novel	
putative	 lncRNA	 loci	 obtained	 by	 RNA-seq.	 This	 algorithm	 employs	 codon	 substitution	
frequencies	in	whole-genome	multi-species	alignments	to	distinguish	between	coding	and	non-
coding	loci.	Whole-genome	alignments	of	46	species	are	obtained	from	the	UCSC	website	and	
processed	 using	 the	 PHAST	 package	 (version	 1.3)	 to	 obtain	 the	 required	 input	 format	 for	
PhyloCSF.		
To	 validate	 our	workflow,	we	 benchmarked	 PhyloCSF	with	 transcripts	 annotated	 in	 Ensembl	





RNA	 samples	 from	 T-ALL	 cells	 treated	 with	 GSI,	 CD34+	 thymocytes	 cultured	 on	 the	 OP9-























means	of	 the	Cytoscape	plug-in	 ‘enrichment	mapping’	 (Isserling	et	al.,	F1000Research,	2014),	















Supplementary	 Figure	 1.	 Validation	 of	 the	 pharmacological	 Notch	 inhibition	 model	 in	 CUTLL1.	 (A)	 Down-






Supplementary	 Figure	2.	Overlap	between	 lncRNAs	 that	 are	negatively	 correlated	with	Notch	 signaling	 in	GSI	
treatment	of	CUTLL1	cells	and	co-culturing	of	CD34+	thymocytes	on	the	OP9-DLL1	feeder	layer.	(A)	Venn	diagram	
depicting	 the	 overlap	 between	 previously	 annotated	 lncRNAs	 that	 are	 up-regulated	 upon	GSI	 treatment	 of	 the	
CUTLL1	 cell	 line	 and	down-regulated	upon	 co-culturing	of	CD34+	 thymocytes	on	 the	OP9-DLL1	 feeder	 layer.	 (B)	
Venn	 diagram	 depicting	 the	 overlap	 between	 previously	 unannotated	 lncRNAs	 that	 are	 upregulated	 upon	 GSI	
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an	 aggressive	 hematologic	 malignancy	 of	
immature	 developing	 precursor	 T-cells	 and	
can	be	classified	 into	different	molecular	ge-
netic	 subgroups	 based	 on	 the	 aberrant	 acti-
vation	of	particular	transcription	factor	onco-
genes.	 In	 addition,	 these	 distinct	 molecular	
entities	 display	 specific	 gene	 expression	 sig-
natures	and	can	be	linked	to	certain	stages	of	
T-cell	development1-4.	Most	genetic	subtypes	
of	 human	 T-ALL	 are	 named	 after	 the	 tran-
scription	 factor	 oncogene	 that	 is	 predomi-
nantly	altered	in	these	hematological	tumors,	
i.e.	TAL/LMO,	TLX1	(HOX11),	TLX3	(HOX11L2)	
or	HOXA.	 However,	 immature	 T-ALLs,	 which	
generally	 lack	 a	 unifying	 molecular	 genetic	
alteration,	are	also	considered	as	a	 separate	
T-ALL	entity	with	putative	clinical	relevance.	
Long	 noncoding	 RNAs	 (lncRNAs)	 are	 a	 novel	
class	 of	 untranslated	 RNAs	 that	 are	 at	 least	
200	nucleotides	 in	size	and	are	 implicated	 in	
a	wide	 variety	 of	 cellular	 functions	 and	 spe-
cific	 developmental	 processes.	 Notably,	 re-
cent	 studies	 have	 shown	 that	 lncRNAs	 can	
drive	tumor	development5,	6	and,	 in	the	con-
text	 of	 T-ALL,	 it	 has	 been	 described	 that	
NOTCH1	 regulates	 the	 expression	 of	 several	
lncRNAs7,	 8.	 One	 interesting	 example	 is	 LU-
NAR1,	 which	 enhances	 the	 expression	 of	
IGF1R,	 leading	 to	 sustained	 IGF1	 signaling8.	
Thus	 far,	 lncRNAs	 remained	 unexplored	 as	
genetic	markers	for	distinct	T-ALL	subtypes.		




ALL	 cell	 lines	 and	 specific	 stages	 of	 normal	
human	 T-cell	 development	 provides	 a	 re-




pathogenesis	 of	 human	 T-ALL,	we	 profiled	 a	
cohort	 of	 64	 T-ALL	 patient	 samples9	 using	 a	
custom	microarray	platform	detecting	13	000	
lncRNAs	 in	 addition	 to	 the	 protein	 coding	
mRNAs10.	This	cohort	consisted	of	RNA	of	15	
immature,	 17	 TLX1/TLX3,	 25	 TAL-R	 and	 7	
HOXA	 positive	 T-ALL	 patients.	 After	 VSN-
normalization,	 background	 subtraction	 was	
executed	by	 retaining	probes	 that	 showed	a	
10	%	higher	expression	 level	as	compared	to	
the	negative	 control	 probes	 in	 at	 least	 60	%	
of	 the	 samples	 of	 one	 particular	 molecular	
genetic	 subgroup.	 In	 keeping	 with	 previous	
reports1,	 2,	 distinct	 molecular	 genetic	 sub-
classes	showed	a	unique	mRNA	gene	expres-
sion	 signature	 (Figure	 1A,	 left	 panel).	 Next,	
we	 used	 the	 5190	 lncRNAs	 that	 showed	 ex-
pression	in	the	T-ALL	patient	cohort	to	define	
subtype	specific	lncRNA	signatures	of	human	
T-ALL.	 The	 top	 50	 differentially	 expressed	
lncRNAs	 for	 each	 subgroup	 are	 represented	
in	Figure	1A	(right	panel).	Of	note,	it	was	not	
possible	 to	 select	50	differentially	expressed	
lncRNAs	 for	 the	 HOXA	 subgroup,	 probably	
due	 to	 the	 small	 amount	of	patient	 samples	
(n=7).	 Forty	 percent	 of	 all	 subtype	 specific	
lncRNAs	 were	 characterized	 as	 ‘lincRNA’	
(long	intergenic	noncoding	RNAs)	in	Ensembl,	
whereas	 33	%	 were	 denoted	 as	 ‘antisense’	
(25	%	had	no	Ensembl	 ID	or	 no	biotype	was	
specified).	 Roughly	 half	 of	 the	 lncRNAs	
showed	 positive	 correlation	 in	 expression	
levels	 with	 one	 or	 more	 protein	 coding	
gene(s)	in	their	vicinity	(500	kb	up-	or	down-
stream	of	 the	 transcription	 start	 site;	 Spear-
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In	 order	 to	 identify	 suitable	 in	 vitro	 model	






ed	 immature	 (LOUCY),	 TLX1/TLX3	 positive	
(ALL-SIL,	DND41	and	HPB-ALL)	and	TAL-R	(PF-
382,	 JURKAT,	 KE-37	 and	 CCRF-CEM)	 tumor	
lines.	 Next,	 we	 used	 gene	 set	 enrichment	
analysis11	 to	 evaluate	 the	 potential	 overlap	
between	the	lncRNA	signatures	from	primary	
T-ALL	 patient	 samples	 and	 the	 established	
tumor	cell	lines	(Figure	1B	and	Supplemental	
Figure	1).	LncRNAs	highly	expressed	in	imma-
ture	 T-ALL	 patients,	 show	 a	 significant	 en-
richment	 in	 the	 immature	 T-ALL	 cell	 line	
LOUCY	 as	 compared	 to	 the	 other	 cell	 lines.	
Similarly,	 TLX1/3	 specific	 lncRNAs	 were	 en-
riched	 in	 ALL-SIL,	 DND-41	 and	 HPB-ALL,	
whereas	TAL-R	associated	lncRNAs	were	pre-
dominantly	 found	 in	 PF-382,	 JURKAT,	 KE-37	
and	CCRF-CEM.	Similar	results	were	obtained	
for	 downregulated	 lncRNAs	 and	 for	 protein	
coding	genes	 (Supplemental	Figure	1	and	2).	
For	 each	 subgroup,	 a	 representative	 lncRNA	
is	 visualized	 by	 means	 of	 RNA-Seq	 and	
H3K27ac	ChIP-Seq	data	of	the	LOUCY,	ALL-SIL	
and	 JURKAT	 T-ALL	 cell	 lines	 (Figure	 1C)12-14.	
Furthermore,	 the	 publically	 available	 RNA-
sequencing	of	8	T-ALL	cell	lines	(LOUCY,	DND-
41,	 HPB-ALL,	 ALL-SIL,	 PF-382,	 JURKAT,	 KE-37	
and	 CCRF-CEM)12	 has	 been	 remapped	 for	
lncRNAs	 and	 subsequently	 GSEA	 has	 been	
performed	 for	 the	 top	 selected	 mRNAs	 and	
lncRNAs	that	were	catalogued	in	the	Ensembl	
database.	 This	 revealed	 that,	 except	 the	
TLX1/3	 upregulated	 lncRNAs,	 all	 subgroup	
specific	gene	sets	were	enriched	in	the	RNA-
sequencing	 data	 of	 the	 corresponding	 T-ALL	
cell	 lines	 of	 that	 particular	 subtype	 (Supple-
mental	 Figure	 3),	 validating	 our	 microarray-
based	 data	 by	 RNA-sequencing.	 We	 hereby	
conclude	that	lncRNA	signatures	in	T-ALL	cell	
lines	 mimic	 those	 observed	 in	 primary	 leu-
kemia	samples	indicating	that	these	cell	lines	
represent	 reliable	 in	 vitro	model	 systems	 to	
study	the	role	of	these	lncRNAs	in	the	patho-
genesis	of	this	disease.		
To	 identify	putative	oncogenic	 lncRNAs	 in	T-
ALL	 development,	 we	 collected	 sorted	 sub-
sets	 of	 healthy	 thymocytes	 (Supplemental	
Methods).	Normal	thymopoiesis	is	a	carefully	
regulated	process	with	 each	of	 the	 interme-
diate	stages	being	characterized	by	a	distinct	
transcriptional	 profile	 and	 a	 combination	 of	
surface	markers	allowing	for	selection	of	the-
se	maturing	T-cell	subsets15.	During	this	mat-
uration	 process,	 several	 oncogenic	 lesions	
can	 occur,	 blocking	 differentiation	 and	 driv-
ing	 these	 immature	 thymocytes	 into	 an	 un-
controlled	 expansion	 towards	 full-blown	 T-
ALL.	 The	 above-described	 T-ALL	 subgroups	
largely	 resemble	 an	 arrest	 of	 thymocytes	 at	
specific	 stages	 of	 T-cell	 development.	 More	
specifically,	 the	 immature	 T-ALL	 patients	
have	an	arrest	in	the	early	stages	of	T-cell	de-
velopment,	 i.e.	 CD34+	 thymocytes.	 In	 con-
trast,	the	leukemic	cells	of	TAL-R	patients	re-
semble	 later	 stages	 of	 T-cell	 development,	
typically	 at	 the	 CD4+CD8+	 double	 positive	
stage.	 Given	 that	 the	 transcriptomes	 of	 the	
different	 genetic	 T-ALL	 subtypes	 strongly	 re-
capitulate	those	of	normal	 immature	thymo-
cytes,	we	also	explored	 the	 lncRNAome	of	6	
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tially	 oncogenic	 lncRNAs.	 (A)	 (left)	Heatmap	 representing	 lncRNAs	of	the	 top	50	 lncRNAs	upregulated	 in	the	













Figure	 4A)	 were	 also	 significantly	 higher	 ex-
pressed	 in	 the	 CD34+	 thymocytes	 as	 com-
pared	 to	 CD4+CD8+	 T-cells	 (Figure	 2A,	 left),	
providing	 a	 link	 between	 immature	 T-ALLs	
and	their	cell	of	origin.	In	contrast,	18	of	the	
top	 50	 showed	 significant	 higher	 expression	
levels	 in	 immature	 T-ALL	 patients	 as	 com-
pared	 to	 CD34+	 thymocytes,	 suggesting	 that	




the	 immature	 T-ALL	 cell	 line	 LOUCY,	making	
them	 top	 candidates	 for	 further	 in	 depth	
study.	
A	similar	analysis	was	performed	for	the	TAL-
R	 subgroup	 in	 relation	 to	 CD4+CD8+	 healthy	
donor	counterparts.	Thirteen	 lncRNAs	of	 the	
top	 50	 upregulated	 in	TAL-R	 T-ALLs	 (Supple-
mental	 Figure	 4B)	 were	 significantly	 higher	
expressed	 in	 the	 CD4+CD8+	 thymocytes	 as	
compared	 to	CD34+	 thymocytes,	 reflecting	 a	
role	 during	 normal	 T-cell	 development	 (Fig-
ure	2A,	right).	On	the	other	hand,	29	lncRNAs	
of	 the	 selection	 are	 potentially	 oncogenic,	
because	 they	 are	 signifycantly	 higher	 ex-
pressed	 in	 the	 TAL-R	 T-ALL	 patients	 com-
pared	with	the	CD4+CD8+	thymocytes	(Figure	
2B	 and	 Supplemental	 Figure	 5B),	 of	which	 9	
are	also	 in	the	core	enrichment	of	the	TAL-R	
T-ALL	cell	lines.		
We	 could	 also	 detect	 possible	 tumor	 sup-
pressive	 lncRNAs	 by	 performing	 the	 reverse	
analysis.	Sixteen	lncRNAs	of	the	top	50	down-
regulated	 lncRNAs	 in	 the	 immature	 patients	
were	 significantly	 higher	 expressed	 in	 the	
CD34+	 thymocytes,	 whereas	 15	 lncRNAs	 of	
the	 top	 50	 downregulated	 lncRNAs	 in	 the	
TAL-R	 patients	 were	 significantly	 higher	 ex-
pressed	 in	 the	 CD4+CD8+	 thymocytes	 (Sup-
plemental	Figure	6).	The	same	analyses	have	
been	 performed	 for	 protein	 coding	 genes,	











sion	 patterns	 of	 the	 top	 50	 upregulated	
lncRNAs	 for	 each	 subgroup	 in	 the	 patients	
from	 that	 specific	 subgroup	 is	 shifted	 to	
higher	 levels,	 suggesting	 that	 these	 lncRNAs	




distinct	 T-ALL	 subgroups	 and	 provides	 a	 re-
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Bone	 marrow	 lymphoblast	 and	 blood	 samples	 from	 T-ALL	 patients	 were	 collected	 after	 in-
formed	 consent	 according	 to	 the	 Declaration	 of	 Helsinki	 from	 Saint-Louis	 Hospital,	 Paris,	
France.	This	study	was	approved	by	the	Institut	Universitair	d’Hématologie	Institutional	Review	
Board	and	the	Ethical	committee	of	Ghent	University	Hospital.	This	primary	T-ALL	cohort	was	





early	 thymocytes.	 A	 total	 thymus	 suspension	 was	 labeled	 with	 CD4,	 CD8	 and	 CD3	 to	 sort	
CD4+CD8+CD3-	and	CD4+CD8+CD3+	double	positive	thymocytes.	








data	was	performed	with	 the	VSN-package	 (BioConductor	 release	3.1)	 in	R.	Background	 sub-
traction	in	the	T-ALL	patient	cohort	was	executed	by	retaining	probes	that	showed	a	10	%	high-
er	expression	level	as	compared	to	negative	control	probes	in	at	 least	60	%	of	the	samples	of	
one	 subgroup.	 Differential	 expression	 analysis	 was	 performed	 in	 R	 using	 Limma.	 Correlation	
analysis	between	protein	coding	genes	and	lncRNAs	was	performed	by	means	of	Spearman	cor-
relation.	Expression	profiling	data	have	been	deposited	in	the	NCBI	Gene	Expression	Omnibus4	









Sample	 Subgroup	 Sample	 Subgroup	 Sample	 Subgroup	
TALL_JS_1	 TAL-R	 TALL_JS_23	 HOXA	 TALL_JS_45	 TLX	
TALL_JS_2	 IMM	 TALL_JS_24	 TAL-R	 TALL_JS_46	 IMM	
TALL_JS_3	 TLX	 TALL_JS_25	 TAL-R	 TALL_JS_47	 TAL-R	
TALL_JS_4	 IMM	 TALL_JS_26	 TLX	 TALL_JS_48	 TAL-R	
TALL_JS_5	 IMM	 TALL_JS_27	 IMM	 TALL_JS_49	 TAL-R	
TALL_JS_6	 HOXA	 TALL_JS_28	 TLX	 TALL_JS_50	 TAL-R	
TALL_JS_7	 IMM	 TALL_JS_29	 IMM	 TALL_JS_51	 TAL-R	
TALL_JS_8	 TAL-R	 TALL_JS_30	 IMM	 TALL_JS_52	 TAL-R	
TALL_JS_9	 TLX	 TALL_JS_31	 TLX	 TALL_JS_53	 TAL-R	
TALL_JS_10	 TLX	 TALL_JS_32	 TAL-R	 TALL_JS_54	 TAL-R	
TALL_JS_11	 HOXA	 TALL_JS_33	 IMM	 TALL_JS_55	 TLX	
TALL_JS_12	 TAL-R	 TALL_JS_34	 TAL-R	 TALL_JS_56	 TLX	
TALL_JS_13	 TAL-R	 TALL_JS_35	 HOXA	 TALL_JS_57	 TLX	
TALL_JS_14	 HOXA	 TALL_JS_36	 TAL-R	 TALL_JS_58	 TLX	
TALL_JS_15	 TAL-R	 TALL_JS_37	 TLX	 TALL_JS_59	 TLX	
TALL_JS_16	 TAL-R	 TALL_JS_38	 IMM	 TALL_JS_60	 TLX	
TALL_JS_17	 IMM	 TALL_JS_39	 TLX	 TALL_JS_61	 HOXA	
TALL_JS_18	 IMM	 TALL_JS_40	 HOXA	 TALL_JS_62	 TLX	
TALL_JS_19	 TLX	 TALL_JS_41	 TAL-R	 TALL_JS_63	 IMM	
TALL_JS_20	 IMM	 TALL_JS_42	 TAL-R	 TALL_JS_64	 TAL-R	
TALL_JS_21	 TAL-R	 TALL_JS_43	 TAL-R	 	 	










was	 performed	 by	 incubation	 of	 the	 chromatin	 fraction	 overnight	 with	 100	 µl	 of	 protein-A	
coated	beads	 (Thermo-Scientific,	 catalog	number	53139)	 and	10	μg	of	H3K27ac-specific	 anti-
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Rank in ordered dataset










Geneset: TOP50 significantly downregulated lncRNAs in
immature T-ALL compared with other T-ALL subtypes
Dataset: 10 T-ALL cell lines














Rank in ordered dataset









Geneset: TOP50 significantly downregulated lncRNAs in
TLX1/3 T-ALL compared with other T-ALL subtypes
Dataset: 10 T-ALL cell lines














Rank in ordered dataset








Geneset: TOP50 significantly downregulated lncRNAs in
TAL-R T-ALL compared with other T-ALL subtypes














































































































































































































































































































































































Rank in ordered dataset








Geneset: TOP50 significantly upregulated mRNAs in
immature T-ALL compared with other T-ALL subtypes
Dataset: 10 T-ALL cell lines
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Rank in ordered dataset








Geneset: TOP50 significantly upregulated mRNAs in
TLX1/3 T-ALL compared with other T-ALL subtypes
Dataset: 10 T-ALL cell lines
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Rank in ordered dataset








Geneset: TOP50 significantly upregulated mRNAs in
TAL-R T-ALL compared with other T-ALL subtypes
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Rank in ordered dataset








Geneset: TOP50 significantly downregulated mRNAs in
immature T-ALL compared with other T-ALL subtypes
Dataset: 10 T-ALL cell lines
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Rank in ordered dataset








Geneset: TOP50 significantly downregulated mRNAs in
TLX1/3 T-ALL compared with other T-ALL subtypes
Dataset: 10 T-ALL cell lines
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Rank in ordered dataset








Geneset: TOP50 significantly downregulated mRNAs in
TAL-R T-ALL compared with other T-ALL subtypes


















































































































































































































































































































































































sis	 in	RNA-sequencing	data	of	8	TALL	 cell	 lines.	 (B)	Gene	 set	enrichment	analysis	of	 the	T-ALL	 subgroup	specific	
downregulated	mRNAs	selected	by	microarray	analysis	 in	RNA-sequencing	data	of	8	TALL	cell	 lines.	 (C)	Gene	set	
enrichment	analysis	of	 the	T-ALL	subgroup	specific	upregulated	 lncRNAs	selected	by	microarray	analysis	 in	RNA-
sequencing	data	of	8	TALL	cell	lines.	(D)	Gene	set	enrichment	analysis	of	the	T-ALL	subgroup	specific	downregulat-
ed	 lncRNAs	selected	by	microarray	analysis	 in	RNA-sequencing	data	of	8	TALL	cell	 lines.	 (A-D)	LOUCY	as	a	repre-
sentative	cell	 line	for	the	immature	T-ALL	subgroup.	DND-41,	HPB-ALL	and	ALL-SIL	as	representative	cell	 lines	for	
the	TLX1/3	T-ALL	subgroup.	PF-382,	 JURKAT,	KE-37	and	CCRF-CEM	as	representative	cell	 lines	 for	the	TAL-R	sub-
group.	























Geneset: TOP50 significantly upregulated mRNAs in
immature T-ALL compared with other T-ALL subtypes
Dataset: RNA sequencing of 8 T-ALL cell lines
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Geneset: TOP50 significantly upregulated mRNAs in
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Geneset: TOP50 significantly upregulated mRNAs in
TAL-R T-ALL compared with other T-ALL subtypes


























Geneset: TOP50 significantly downregulated mRNAs in
immature T-ALL compared with other T-ALL subtypes
Dataset: RNA sequencing of 8 T-ALL cell lines





















Geneset: TOP50 significantly downregulated mRNAs in
TLX1/3 T-ALL compared with other T-ALL subtypes
Dataset: RNA sequencing of 8 T-ALL cell lines
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Geneset: TOP50 significantly downregulated mRNAs in
TAL-R T-ALL compared with other T-ALL subtypes


























Geneset: TOP50 significantly upregulated lncRNAs in
immature T-ALL compared with other T-ALL subtypes
Dataset: RNA sequencing of 8 T-ALL cell lines





















Geneset: TOP50 significantly upregulated lncRNAs in
TAL-R T-ALL compared with other T-ALL subtypes


























Geneset: TOP50 significantly downregulated lncRNAs
in immature T-ALL compared with other T-ALL subtypes
Dataset: RNA sequencing of 8 T-ALL cell lines
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Geneset: TOP50 significantly downregulated lncRNAs
in TAL-R T-ALL compared with other T-ALL subtypes
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Long	noncoding	RNAs	are	emerging	as	 important	players	 in	cancer.	 In	order	to	identify	candi-
date	oncogenic	lncRNAs,	we	have	performed	a	broad	and	in	depth	comparative	landscaping	of	
the	lncRNAomes	of	all	genetic	T-ALL	subtypes	and	normal	counterpart	T-cell	subsets.	First,	we	
validated	 our	 previous	 lncRNA	 T-ALL	 subgroup	 classification	 and	 showed	 that	 poly(A)	 RNA-
sequencing	 allows	more	 robust	 classification	 as	 compared	 to	 array-based	 analysis.	 Next,	 we	
identified	 ectopically	 expressed	 candidate	 oncogenic	 lncRNAs	 in	 immature	 and	 TAL-R	 T-ALL,	
which	represent	valid	targets	for	functional	studies.	In	addition,	using	total	RNA-sequencing	on	
a	 smaller	 subset	 of	 samples,	we	 investigated	 the	 full	 spectrum	 of	 long	 noncoding	 RNAs	 and	









into	 different	 genetic	 subtypes	 based	 upon	
their	 aberrant	 expression	 of	 specific	 tran-
scription	 factor	 oncogenes	 (TAL,	 TLX1,	 TLX3	
or	HOXA)	 that	 demarcates	 a	 developmental	
arrest	at	a	specific	stage	of	T-cell	differentia-
tion1-4.	 More	 than	 a	 decade	 ago,	 a	 unique	
mRNA	 expression	 signature	 characterizing	




Previous	 studies	 describing	 T-ALL	 signatures	
were	 based	 on	 the	 profiling	 of	 the	 T-ALL	
samples	by	micro-array	platforms,	with	a	cus-
tom	 designed	 micro-array	 platform	 for	 the	
detection	 of	 lncRNAs5,	 6.	 	 Currently,	 RNA-
sequencing	offers	 a	more	powerful	platform	
for	 sensitive	 detection	 of	 lncRNAs	 including	
those	 who	 have	 not	 been	 previously	 anno-
tated.		
Here,	we	analyzed	poly(A)	RNAseq	mRNA	and	
lncRNA	 profiles	 of	 60	 primary	 T-ALL	 patient	
samples	 from	 four	 different	 genetic	 T-ALL	
subtypes	 (immature,	 TLX1/3,	 TAL-R	 and	
HOXA	overexpressing	T-ALL)	by	poly(A)	RNA-
seq.	We	 validated	 our	 dataset	 through	 sub-
group	 classification	 and	 show	 more	 robust	
separation	by	RNA-seq	as	compared	to	array-
data.	 Next,	 we	 identified	 ectopically	 ex-
pressed	 candidate	 oncogenic	 lncRNAs	
through	 comparison	 with	 normal	 thymo-
cytes.	Finally,	we	detect	novel	T-ALL	lncRNAs,	
in	particular	in	a	subset	of	25	primary	match-




Blood	 samples	 and	 bone	 marrow	 lympho-
blast	from	T-ALL	patients	were	collected	after	
informed	 consent	 according	 to	 the	 Declara-
tion	 of	 Helsinki	 from	 Saint-Louis	 Hospital,	
Paris,	 France.	 This	 study	 was	 approved	 by	
both	 the	 Institut	 Universitair	 d’Hématologie	








hort	 previously	 investigated	 by	 mRNA8	 and	
lncRNA	profiling5,	9.		
Thymocyte	subset	selection	
Thymus	 tissue	was	 derived	 from	 a	 child	 un-
dergoing	 cardiac	 surgery	 (UZ	Gent)	 and	was	
obtained	 and	 used	 according	 to	 the	 guide-
lines	 of	 the	 Medical	 Ethical	 Commission	 of	
Ghent	 University	 Hospital	 (Ghent,	 Belgium).	
Immature	 CD34+	 thymocytes	 were	 purified	
based	 on	MACS	 purification	 using	 CD34	mi-
crobeads	(Miltenyi	Biotec)10	and	were	subse-
quently	sorted	into	a	CD1	negative	and	posi-
tive	 subpopulation.	 On	 the	 other	 hand,	 the	
CD4+CD8+	double	positive	subset	was	isolated	
using	 CD4	 and	 CD8	 labeled	 antibodies	 and	
was	 further	 divided	 into	 the	 CD3	 negative	
and	the	more	mature	CD3	positive	subpopu-
lations.	 All	 sorts	 were	 performed	 using	 a	
FACSAriaIII	 (BDBiosciences).11	 The	 purity	 of	
each	subset	was	at	least	98%.	Total	RNA	was	




using	 the	 TruSeq	 Stranded	 mRNA	 sample	
prep	 kit	 (Illumina).	 100	 ng	 of	 total	 RNA	was	
enriched	 using	 the	 oligodT	 bead	 system	 (Il-
lumina).	The	isolated	mRNA	was	subsequent-
ly	 fragmented	 using	 enzymatic	 fragmenta-
tion.	 Libraries	 for	 total	 RNA-seq	 were	 pre-
pared	 using	 the	 TruSeq	 Stranded	 total	 RNA	
(with	RiboZero	Gold)	sample	prep	kit	 (Illumi-
na).	 100	 ng	 of	 total	 RNA	 was	 depleted	 of	
rRNAs	 using	 Ribo-Zero	 Gold	 magnetic	 bead	
based	 capture-probe	 system	 (Illumina).	 The	
remaining	 RNA	 was	 subsequently	 purified	
(RNAcleanXP)	 and	 fragmented	 using	 enzy-
matic	fragmentation.	
First	 and	 second	 strand	 synthesis	 was	 per-
formed	and	double	stranded	cDNA	was	puri-
fied	 (Agencourt	 AMPure	 XP).	 The	 cDNA	was	
end-repaired,	 3’adenylated	 and	 Illumina	 se-
quencing	 adapters	 were	 ligated	 followed	 by	
purification.	 The	 mRNA	 stranded	 libraries	
were	 pre-amplified	 with	 PCR	 and	 purified	
(Agencourt	 AMPure	 XP).	 The	 quality	 of	 the	
libraries	was	 inspected	 on	 the	 2100	 Bioana-
lyzer	(high	sensitivity	DNA	chip,	Agilent).	High	
quality	 libraries	 were	 quantified	 using	 the	
Qubit	 Fluorometer	 (Life	 Technologies).	 After	
concentration	 normalization,	 single-end	 se-
quencing	was	performed	on	the	NextSeq500	
instrument	 (Illumina)	 according	 to	manufac-
turer	instructions.	
RNA-seq	data-processing	
Reads	 were	 mapped	 to	 the	 reference	 ge-
nome	GRCh38	with	 STAR	 v2.4.2a.	 STAR	was	
also	 used	 for	 gene	 expression	 quantification	
on	Gencode	v23	GTF.	For	each	sample,	tran-
script	 assembly	 was	 performed	 with	 String-
Tie.	 Subsequently	 Cuffmerge	 was	 used	 to	
merge	 all	 transcript	 assemblies	 into	 one	 su-
perset	containing	all	transcripts	present	in	at	
least	one	 sample.	Expression	 levels	are	visu-
alized	 as	 Transcripts	 Per	 Kilobase	 Million	
(TPM),	which	is	calculated	by	first	dividing	all	
read	counts	by	their	gene	length	in	kilobases	
(RPK,	 reads	 per	 kilobase)	 and	 subsequently	
by	the	scaling	factor	per	sample.	This	scaling	
factor	 was	 determined	 by	 summing	 up	 all	
RPK	values	per	sample	and	dividing	this	by	1	
million.		
To	 identify	 unannotated	 transcripts,	 the	
merged	GTF	file	was	compared	with	different	
annotation	 GTF	 files	 (Gencode23,Refseq78,	








was	 filtered	 with	 a	 background	 correction	
that	 only	 retained	 the	 genes	 detected	 by	 at	
least	4	reads	in	at	least	60%	of	samples	from	
one	T-ALL	subgroup	or	in	at	least	all	samples	
from	 one	 thymocyte	 subset.	 Differential	 ex-
pression	 analysis	 was	 performed	 using	 the	
DESeq2	algorithm	in	R12.		
RESULTS	
Validation	 of	 the	 poly(A)	 RNA-sequencing	
dataset	of	T-ALL	patient	samples	through	T-
ALL	genetic	subtype	classification			
Poly(A)	 RNA-sequencing	 was	 performed	 for	
60	primary	T-ALL	patient	samples	with	an	av-
erage	 sequencing	 depth	 of	 51	 million	 reads	
per	 sample,	 of	which	65%	 could	be	mapped	
to	 the	 Gencode	 v23	 database13,14.	 The	 60	
samples	are	divided	over	the	four	main	T-ALL	
subtypes:	 13	 immature,	 17	 TLX1/3	 overex-
pressing,	 23	 TAL-rearranged	 and	 7	 HOXA	
overexpressing	 cases	 (Figure	 1A).	 To	 correct	
for	 background	 detection,	 only	 genes	 that	
were	detected	by	at	 least	 four	 reads	 in	60%	
of	the	samples	of	one	particular	genetic	sub-
type	 were	 retained	 (14,447	 protein	 coding	
genes	 and	 3,264	 lncRNAs	 (‘lincRNA	 or	 ‘anti-
sense’	 biotype)).	 The	expression	 level	 of	 the	
lncRNAs	is,	as	expected,	much	lower	than	for	
protein	 coding	genes,	 as	 can	be	appreciated	
from	the	density	plot	(Figure	1B).		
Principal	 Component	Analysis	 (PCA)	 shows	a	
clustering	 of	 the	 samples	 according	 to	 sub-
type	for	both	the	mRNA	(Supplementary	Fig-
ure	 1A)	 and	 lncRNA	 (Figure	 1C)	 expression,	
with	 the	 only	 exception	 for	 the	HOXA	 sam-
ples	 which	 are	 broadly	 dispersed.	 Hierar-
chical	clustering	of	the	samples,	using	the	top	
1000	 mRNAs	 or	 top	 1000	 lncRNAs	 with	 the	
largest	standard	deviation,	also	shows	a	sep-
aration	of	most	of	 the	 immature,	TAL-R	 and	
TLX1/3	patient	samples	to	the	expected	sub-
type	 based	 on	 clinical	 data	 (Supplementary	
Figure	2).	Notably,	lncRNA	expression	profiles	
yield	a	similar	qualitative	separation	of	T-ALL	
subtypes	 as	 hierarchical	 clustering	 based	 on	
protein	coding	gene	expression	profiles.		
To	 identify	 the	 subtype	 specific	 lncRNAs	 in	
our	 poly(A)	 RNA-seq	 dataset,	 we	 performed	
DESeq2	 differential	 expression	 analysis12	 us-
ing	 iterations	 of	 one-to-three	 comparisons.	
We	validated	this	method	based	on	the	pro-
tein	 coding	 gene	 expression	 and	 detected	
several	 specific	 mRNAs	 that	 were	 already	
identified	by	previous	groups	(Supplementary	
Figure	 1B,	 Supplementary	 Table	 1)1,2.	 The	
heatmap	 in	 Figure	1D	 represents	 the	 top	50	
most	 differentially	 expressed	 lncRNAs	 per	
subgroup.	 Again,	 this	 pattern	 is	 less	 distinct	
for	the	HOXA	group	as	only	48	HOXA-specific	
lncRNAs	 could	 be	 identified.	 For	 the	 other	
subtypes,	 at	 least	 550	 lncRNAs	 were	 signifi-
cantly	 up	 or	 downregulated	 (p.adj	 <	 0.05)	
(Supplementary	Table	2).	




further	 functional	 analysis	 of	 candidate	 on-
cogenic	 lncRNAs,	 we	 therefore	 analyzed	
lncRNA	profiles	of	commonly	used	T-ALL	cell	
lines	 in	 a	 publicly	 available	 poly(A)	 RNA-seq	
data15.	 The	 LOUCY	 cell	 line	 is	 representative	
for	 the	 immature	 T-ALL	 patients,	 whereas	
HPB-ALL	(TLX3+),	DND-41	(TLX3+)	and	ALL-SIL	
(TLX1+)	 represent	 the	TLX1/3	 T-ALL	 subtype.	
The	 TAL-R	 subtype	 can	 be	 linked	 to	 the	 cell	









regulated	 lncRNAs	 for	 the	 immature,	TLX1/3	
or	TAL-R	subgroups	represented	by	the	verti-
cal	 black	 bars.	 We	 therefore	 conclude	 that	
nearly	all	of	selected	overexpressed	 lncRNAs	
are	 also	 detected	 at	 relatively	 high	 levels	 in	
the	 representative	 cell	 lines	 validating	 their	
use	for	further	study	of	the	oncogenic	effect.		
To	further	explore	the	T-ALL	subtype	specific	
lncRNAs	 in	 T-ALL	 cell	 lines,	 we	 performed	
Gene	 Set	 Enrichment	 Analysis	 (GSEA)	 with	
the	top	50	up-	or	downregulated	lncRNAs	per	




subtype.	 For	 the	 upregulated	 lncRNAs	 per	
subtype,	 there	was	only	 a	 significant	enrich-
ment	for	the	TAL-R	 lncRNAs	in	the	TAL-R	cell	
lines.	 For	 the	 immature	 and	TLX1/3	 upregu-
lated	 lncRNAs,	 several	 were	 also	 higher	 ex-
pressed	 in	 their	 representative	 cell	 lines	 as	
compared	to	the	others,	but	the	full	geneset	












Poly(A)	 RNA-sequencing	 detects	 subtype	
specific	 lncRNAs	more	 robustly	 than	micro-
array	profiling	
We	previously	published	the	subtype	specific	
mRNA	 and	 lncRNA	 signatures	 of	 these	 pa-
tients	based	on	micro-array	expression	profil-
ing5.	 If	we	 compare	both	 signatures	 for	pro-
tein	coding	genes,	we	 find	50-80%	of	signifi-
cant	 subtype	 specific	 mRNAs	 detected	 by	
poly(A)	 RNA-seq	 also	 in	 our	 microarray	 da-
taset	(Supplementary	Figure	5A).	This	overlap	
is	 however	 smaller	 (less	 than	 30%)	 for	 the	
HOXA-specific	 mRNAs,	 but	 again,	 this	 might	
be	 due	 to	 the	 low	 number	 of	 patient	 sam-
ples.	 However,	 with	 poly(A)	 RNA-seq,	 much	
more	 HOXA-specific	 mRNAs	 were	 detected.	
Remarkably,	if	we	compared	the	mRNAs	that	
were	 subtype	 specific	 by	 both	methods,	 the	
detected	fold	change	was	significantly	(Paired	
students	t-test;	p	<	0,01)	larger	for	the	micro-
array	 profiling	 of	 the	 immature,	 TLX1/3	 and	
HOXA	signatures	(Supplementary	Figure	5B).		
To	 compare	 the	 lncRNA	 signatures	 obtained	
from	both	methods,	we	had	to	cope	with	the	
different	 annotation	 of	 the	 micro-array	
probes	compared	to	our	poly(A)	RNA-seq	da-
taset.	As	a	consequence,	we	could	only	con-
vincingly	 compare	 860	 Gencode	 defined	
lncRNAs	 (‘lincRNA’	 and	 ‘antisense’	 biotype)	
with	probes	on	the	micro-array	and	took	only	
these	lncRNAs	into	account	for	further	analy-
sis.	 For	 the	 T-ALL	 subtype	 specific	 lncRNAs,	
we	 detected	 an	 overlap	 of	 about	 50%	 be-
tween	both	methods	(Figure	3A).	In	compari-
son	 to	 the	 protein	 coding	 genes,	 the	 fold	
change	of	the	subtype	specific	lncRNAs	in	the	











































































































































































































































































































































































































We	 next	 took	 advantage	 of	 the	 power	 of	
RNA-sequencing	 for	 the	 detection	 of	 novel	
lncRNAs.	 To	 this	 end,	 we	 aligned	 our	 RNA-
sequencing	 reads	with	 the	 STAR	 algorithm16	
to	 the	 hg38	 genome,	 followed	 by	 transcript	
assembly	 with	 StringTie17.	 These	 transcript	
assemblies	 per	 sample	were	 then	 combined	
with	Cuff-Compare18	 leading	 to	 the	 in-house	
establishment	 of	 a	 T-ALL	 transcriptome	 (an-
notated	 with	 XLOC	 codes).	 This	 led	 to	 the	
identification	of	12,524	genes	 that	were	not	
present	 in	Gencode	 (v23)13,	Ensembl	 (v81)19,	
RefSeq	(v78)20	and	lncipedia	(v3.1)21.	To	elim-
inate	 very	 low	 expressed	 genes,	 we	 per-
formed	a	background	correction	in	which	we	
only	 retained	 the	 3303	 genes	 that	were	 de-
tected	by	 at	 least	 4	 reads	 in	 at	 least	 5	 sam-
ples.	 Furthermore,	 there	 is	 more	 evidence	
that	a	gene	 is	 truly	 functional	 if	at	 least	one	
splicing	 event	 occurs,	 so	 we	 filtered	 out	








































































































































































































































































































































































Figure	3.	Poly(A)	RNA-seq	detects	subtype	specific	 lncRNAs	more	 robustly	than	micro-arrays.	 (A)	Overview	of	
the	 amount	 of	 subtype	 specific	 lncRNAs	 detected	 only	 by	 micro-array	 profiling	 (dark	 blue),	 only	 by	 RNA-









these	 genes	 are	 thus	 considered	 as	 novel	
lncRNAs	 (Supplementary	 table	 3).	 Of	 these	
526	lncRNAs,	511	were	intergenic,	3	were	an-
tisense	 and	 12	 were	 bi-directional	 (having	
their	 transcription	 start	 site	 closer	 than	 100	
bp	 from	the	transcription	start	site	of	a	pro-
tein	coding	gene).		
We	 repeated	 the	 differential	 expression	
analysis	 for	 lncRNAs	between	the	T-ALL	sub-
types,	 but	 this	 time,	 we	 added	 the	 novel	
identified	 lncRNAs	 to	 these	 already	 included	
by	Gencode	(v23)13,	14.	Several	of	these	puta-
tively	 novel	 lncRNAs	 were	 also	 significantly	
up-	 or	 downregulated	 in	 a	 specific	 subtype	
and	interestingly,	some	of	these	were	repre-
sented	 in	 the	 top	 50	 most	 significantly	 up-
regulated	 lncRNAs.	 For	 each	 subtype,	 the	
most	 significant	 upregulated	 novel	 lncRNA,	
which	 was	 also	 present	 in	 the	 top	 50	 of	 all	
lncRNAs,	 is	 shown	 in	 Figure	4B.	 It	 should	be	




the	 TLX1/3	 subtype	 and	 detected	 at	 quite	
high	 rates	 in	 the	 HPB-ALL	 and	 DND41	 cell	
lines	(TLX3+,	data	not	shown).	Also	the	other	
novel	 subtype	 specific	 lncRNAs	 are	 repre-
sented	in	the	cell	lines,	however	at	a	low	lev-
el.		
Comparative	 analysis	 of	 normal	 thymocyte	
versus	 T-ALL	 lncRNA	 transcriptomes	 identi-
fies	oncogenic	lncRNAs	
T-ALL	 occurs	 from	 a	 malignant	 transfor-
mation	of	maturing	T-cells	in	the	thymus.	The	
lymphoblasts	 of	 the	 immature	 T-ALL	 cases	
show	a	differentiation	arrest	very	early	dur-	
Figure	4.	Poly(A)	RNA-seq	can	link	previously	unannotated	lncRNAs	to	specific	T-ALL	subtypes.	(A)	Overview	
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ing	 T-cell	 development,	 at	 the	 CD34+	 stage.	
The	TAL-R	 cases	however,	have	had	a	differ-
entiation	arrest	at	a	later	stage	during	devel-
opment,	 from	 the	 CD4+CD8+	 double	 positive	
stage	on.	To	 identify	oncogenic	 lncRNAs,	we	
profiled	 the	 lncRNA	 expression	 of	 2	 CD34+	
and	 2	 CD4+CD8+	 subsets	 from	 a	 healthy	 do-
nor	by	poly(A)	RNA-sequencing.			
By	 means	 of	 differential	 RNA-seq	 analysis	
(DESeq2),	 we	 identified	 276	 lncRNAs	 that	
were	 upregulated	 in	 immature	 T-ALL	 com-
pared	 to	 the	 CD34+	 healthy	 donor	 subsets	
(Figure	 5A,	 Supplementary	 Table	 4).	 Sixteen	
of	 these	 lncRNAs	were	 also	 identified	 in	 the	
top	 50	 upregulated	 lncRNAs	 in	 immature	 T-
ALL	compared	to	the	other	subtypes	(two	ex-
amples	 in	 Figure	 5B).	 These	 16	 lncRNAs	 are	
thus	 potential	 oncogenic	 drivers	 for	 imma-
ture	 T-ALL.	 Furthermore,	 475	 lncRNAs	 were	
upregulated	 in	 TAL-R	 T-ALL	 as	 compared	 to	
Figure	 5.	 Comparison	with	 thymocyte	 subsets	 detects	 oncogenic	 subtype	 specific	 lncRNAs.	 (A)	Diagonal	plot	
comparing	 the	 expression	 of	 lncRNAs	 between	 IMM	 T-ALL	 samples	 and	 CD34+	 T-cell	 subsets.	 Red	 dots	 are	
lncRNAs	significantly	upregulated	in	IMM	T-ALL	and	blue	dots	are	the	significantly	downregulated	lncRNAs	(p.adj	
<	0.05).	 (B)	Two	examples	of	 IMM	T-ALL	upregulated	 lncRNAs	 that	are	also	upregulated	 in	 IMM	T-ALL	as	 com-
pared	to	their	healthy	donor	counterparts.	(C)	Diagonal	plot	comparing	the	expression	of	lncRNAs	between	TAL-R	

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































50	 upregulated	 lncRNAs	 in	TAL-R	 T-ALL	 (Fig-
ure	5D).		
Comparison	 of	 poly(A)	 and	 total	 RNA	 se-
quencing	data	sets	for	unannotated	lncRNAs	
As	 a	 last	 part	 of	 this	 study,	 we	 evaluated	
whether	 additional	 information	 can	 be	 ob-
tained	on	lncRNA	expression	profiles	of	T-ALL	
samples	by	means	of	 total	RNA-seq	 (with	 ri-
bodepletion)	 as	 compared	 to	 poly(A)	 RNA-
seq.	A	first	 incentive,	 is	 that	several	 lncRNAs	
do	 not	 have	 a	 poly(A)	 tail,	 so	 these	 will,	 by	
definition,	 not	 be	 detected	 by	 poly(A)	 RNA-
seq.	It	should	however	be	stated	that	we	de-
tect	some	known	non-poly(A)	genes	(ex.	his-
tone	 genes	 and	 MALAT1	 lncRNA)	 in	 our	
poly(A)	 dataset	 as	 some	 random	 priming	
might	occur	during	 library	preparation,	how-
ever	 these	genes	are	only	detected	at	a	 low	
ratio.	 One	 disadvantage	 of	 total	 RNA-seq	 is	
the	cost,	as	 the	sequencing	depth	should	be	




overexpressing	 T-ALL	 cases)	 also	 profiled	 by	
poly(A)	RNA-seq.	 The	average	 read	depth	of	
the	total	RNA-seq	was	103	million	reads,	with	
45	million	 reads	mapping	 to	Gencode	 (v23).	
To	perform	an	optimal	 comparison	between	
both	technologies,	we	also	selected	only	the	
matching	 25	 samples	 out	 of	 our	 poly(A)	 da-






tein	 coding	 potential	 calculation	 (CPC22)	 fur-
ther	 identified	 712	 novel	 lncRNAs	 in	 the	
poly(A)	data	and	831	novel	lncRNAs	in	the	to-
tal	 RNA-seq	 data,	 with	 an	 overlap	 of	 611	
lncRNAs	(Figure	6,	Supplementary	Table	5).	In	
this	 respect,	 it	 might	 be	 interesting	 to	 per-
form	 total	RNA-seq	as	 it	detects	more	novel	
lncRNAs	than	poly(A)	RNA-seq.	If	we	also	look	
at	 the	annotated	mRNAs	and	 lncRNAs	 in	the	
Gencode	 database,	 we	 also	 detect	 more	
genes	 in	 total	 RNA-seq	 after	 a	 background	
correction	 (more	 than	 four	 reads	 in	 at	 least	
two	 samples	 of	 one	 T-ALL	 subtype).	 With	
poly(A)	RNA-seq	we	detected	15,858	protein	
coding	genes	and	4,720	lncRNAs	and	with	to-
tal	 RNA-seq	 there	were	 16,388	 protein	 cod-
ing	 genes	 and	 5,759	 lncRNAs.	 A	 pairwise	
comparison	 between	 the	 samples	 also	 re-




does	 not	 only	 detect	more	novel	 genes,	 but	
also	more	known	genes.		
Figure	6.	Total	RNA-sequencing	detects	more	previ-
ously	 unannotated	 lncRNAs	 compared	 to	 poly(A)	
RNA-seq.	Venn	 diagram	 representing	 the	amount	 of	







T-ALL	 genetic	 subtypes	 have	 already	 been	
linked	 in	 the	 past	 to	 specific	 mRNA	 profiles	
and	more	 recently	our	 research	 team	estab-
lished	 subgroup	 specific	 lncRNA	 expression	
profiles	by	micro-array	technology1,	2,	5.	In	this	
study,	 we	 profiled	 gene	 expression	 of	 60	 T-
ALL	patient	samples	divided	over	the	several	
subtypes	 by	 poly(A)	 RNA-sequencing.	 First,	
we	could	confirm	that	patients	from	a	specif-
ic	subtype	cluster	together	by	their	gene	ex-
pression	 profiles,	 either	 for	 mRNAs	 or	 for	
lncRNAs	and	defined	an	updated	lncRNA	sig-
nature	for	the	subtypes	(Figure	1).	By	using	a	
publically	 available	 unstranded	 poly(A)	 RNA-
seq	dataset	of	T-ALL	cell	 lines,	we	could	also	
verify	 the	expression	of	 the	 subtype	 specific	
lncRNAs	in	matching	T-ALL	cell	lines.	Most	of	
the	 denoted	 signatures	 were	 linked	 to	 the	
subtype	 specific	 cell	 lines,	 however	 there	
were	 some	 exceptions	 (Figure	 2).	 These	 ex-
ceptions	might	be	due	to	the	different	nature	
of	the	RNA-sequencing	datasets,	as	our	T-ALL	
patient	 cohort	 was	 a	 stranded	 poly(A)	 da-
taset	and	the	publicly	available	T-ALL	cell	line	
data	 was	 unstranded.	 Furthermore,	 using	
poly(A)	 RNA-seq	 data	 of	 healthy	 donor	 thy-
mocytes	 we	 could	 identify	 ectopically	 ex-
pressed	 subtype	 specific	 lncRNAs	 for	 imma-
ture	T-ALL	and	TAL-R	T-ALL	(Figure	5)	
We	could	compare	this	dataset	with	the	pre-
viously	 published	 micro-array	 data5,	 as	 the	
same	 patient	 cohort	 was	 used.	 For	 protein	
coding	 genes,	 there	 was	 a	 big	 overlap	 be-
tween	 the	 2	 datasets	 and	 for	 this	 analysis,	
poly(A)	RNA-sequencing	did	not	 immediately	
give	 an	 advantage.	However,	 it	might	 be	 in-
teresting	 to	 check	 this	 poly(A)	 dataset	 for	
specific	 transcripts	 or	 splicing	 variants	 of	
mRNAs	present	in	the	subtypes,	but	this	falls	
beyond	 the	 scope	 of	 this	 paper.	 In	 terms	 of	
lncRNAs,	 the	overlap	between	both	datasets	
was	 quite	 difficult	 and	 we	 could	 only	 com-
pare	 a	 small	 amount	 of	 lncRNAs.	 Still,	 there	
was	 quite	 some	 overlap	 between	 both	 sub-
type	specific	signatures.	Remarkably,	lncRNAs	
that	 were	 denoted	 as	 significant	 by	 both	
methods	 had	 a	 larger	 fold	 change	 in	 the	
poly(A)	 RNA-seq	 dataset.	 This	 could	 imply	
that	 poly(A)	 RNA-seq	 has	 the	 possibility	 to	
better	 determine	 the	 differential	 expression	
for	 lncRNAs	 than	 micro-arrays	 have	 (Figure	
3).	
Another	 advantage	 of	 poly(A)	 RNA-
sequencing	over	micro-array	data	 is	the	pos-
sibility	 to	detect	novel,	unanotated	 lncRNAs.	
This	 can	 be	 very	 interesting,	 as	 lncRNAs	 are	
known	to	be	 tissue	or	even	cell-type	specifi-




any	 other	 RNA-seq	 study.	 In	 our	 poly(A)	 da-
taset	 of	 60	 T-ALL	 samples,	we	 detected	 526	




expression	 level	 (at	 least	 4	 reads	 in	 5	 sam-
ples),	 the	 need	 for	 a	 splicing	 event	 and	 no	
protein	 coding	 potential	 (calculated	 with	
CPC22).	It	should	be	noted	that	unspliced,	sin-
gle-exon	 transcripts	 might	 also	 be	 interest-
ing,	as	they	can	for	example	be	linked	to	the	
class	 of	 enhancer	 RNAs23.	 Several	 novel	
lncRNAs	 are	 also	 subtype	 specifically	 ex-
pressed	 and	 are	 even	 present	 in	 the	 top	 50	
most	 significant	 lncRNAs	 (annotated	 and	
novel)	 for	 a	 subtype	 (Figure	 4).	 However,	 it	
should	be	 interesting	 to	also	add	CAGE	 (Cap	
Analysis	 Gene	 Expression)	 data	 and	 histone	









samples	 to	 test	 if	 total	 RNA-sequencing	
would	give	an	extra	benefit	over	poly(A)	RNA-
seq	 to	 detect	 lncRNAs	 in	 T-ALL.	 With	 total	
RNA-sequencing,	more	known	protein	coding	
genes	 and	 lncRNAs	 were	 detected	 and	 we	
could	 also	 show	 that	more	 novel	 previously	
unannotated	 lncRNAs	 were	 detected.	 Fur-
thermore,	total	RNA-seq	could	be	interesting	
to	 possibly	 detect	 circular	 RNAs24	 or	 other	
non	poly-adenylated	RNA	transcripts	 (for	ex.	
snoRNAs).		
With	 this	 study,	we	updated	 the	 lncRNA	sig-
natures	 of	 T-ALL	 subtypes	 by	 poly(A)	 RNA-
sequencing	and	could	show	that	poly(A)	RNA-
seq	 has	 an	 advantage	 over	 the	 previously	
used	micro-array	 profiling.	 Next	 to	 that,	 we	
also	 identified	 several	 novel,	 previously	 un-
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Supplementary	 Figure	 3.	 Poly(A)	 RNA-seq	 of	 T-ALL	 cell	 lines.	Density	plots	of	 lncRNA	expression	 in	 the	
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Geneset: TOP50 upregulated lncRNAs in immature T-ALL
compared to other T-ALL subtypes
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Geneset: TOP50 downregulated lncRNAs in immature T-ALL
compared to other T-ALL subtypes
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Geneset: TOP50 downregulated lncRNAs in TLX1/3 T-ALL
compared to other T-ALL subtypes
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Geneset: TOP50 upregulated lncRNAs in TLX1/3 T-ALL
compared to other T-ALL subtypes
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Geneset: TOP50 upregulated lncRNAs in TAL-R T-ALL
compared to other T-ALL subtypes
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Geneset: TOP50 downregulated lncRNAs in TAL-R T-ALL
compared to other T-ALL subtypes

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(dark	 blue),	 only	 by	 RNA-sequencing	 (light	 blue)	 or	 by	 both	methods	 (red).	 (B)	 Comparison	 between	micro-
















Comprehensive	 miRNA	 expression	 profiling	 in	 human	 T-cell	 acute	
lymphoblastic	leukemia	by	small	RNA-sequencing	
	
































is	 classified	 into	 different	 genetic	 subtypes	
based	 upon	 the	 aberrant	 expression	 of	 spe-
cific	 transcription	 factor	 oncogenes	 (TAL,	
TLX1,	TLX3	or	HOXA)	or	the	arrest	at	a	specif-
ic	stage	of	T-cell	differentiation	(immature	T-





MicroRNAs	 (miRNAs)	 are	 short	 noncoding	
RNAs	 that	 function	 as	 post-transcriptional	
repressors	of	specific	target	genes.6,	7	Several	
studies	 have	 previously	 described	 a	 role	 for	
miRNAs	 in	 malignant	 T-cell	 transformation,	
including	 the	 identification	of	both	an	onco-
genic	 (miR-19b,	 mir-20a,	 miR-26a,	 miR-92	
and	miR-223)	8	as	well	as	a	tumor	suppressor	
(miR-150,	 miR-155,	 miR-200	 and	 miR-193b-
3p)	9,	10	miRNA	network	involved	in	T-ALL	dis-
ease	 biology.	 However,	 studies	 that	 ad-





More	 recently,	 small	 RNA-sequencing	
emerged	 as	 a	more	 comprehensive	 technol-
ogy	 that	 enables	 unbiased	 detection	 of	 the	
full	 spectrum	of	small	RNA	molecules.	 In	ad-
dition,	it	also	provides	information	on	specific	
isoforms	 that	 differ	 from	 canonical	 miRNAs	
by	 the	 addition	 or	 deletion	 of	 one	 or	 more	
nucleotides	 at	 the	 5’	 or	 3’	 end	 of	 the	
miRNA.11,	 12	 Notably,	 this	 heterogeneity	 in	
miRNA	sequences,	which	is	thought	to	result	
from	 RNA-editing,	 exonuclease	 activity	 or	
imprecise	 cleavage	 by	DICER	 or	DROSHA	 (ri-
bonucleases	 involved	 in	 the	 miRNA	 pro-
cessing)	 13,	 could	 be	 functionally	 relevant	 as	
shown	for	a	number	of	miRNAs.14-17	
Here,	 we	 used	 small	 RNA-sequencing	 to	
study	 the	 full	 spectrum	 of	 miRNAs	 that	 are	
expressed	 in	 human	 T-ALL	 samples.	 We	
demonstrate,	for	the	first	time,	that	molecu-
lar	 genetic	 subtypes	 of	 human	 T-ALL	 are	
characterized	 by	 unique	 miRNA	 expression	
	170	
signatures,	 delineate	 the	 pattern	 of	 miRNA	
isoforms	 that	 are	 expressed	 in	malignant	 T-
cells	 and	 use	 small	 RNA	 sequencing	 profiles	
of	normal	T-cell	subsets	to	identify	novel	pu-





primary	 T-ALL	 patient	 samples,	 7	 T-ALL	 cell	
lines	 and	 2	 CD34+	 and	 2	 CD4+CD8+	 healthy	




Blood	 samples	 and	 bone	 marrow	 lympho-
blast	from	T-ALL	patients	were	collected	after	
informed	 consent	 according	 to	 the	 Declara-
tion	 of	 Helsinki	 from	 Saint-Louis	 Hospital,	
Paris,	 France.	 This	 study	 was	 approved	 by	
both	 the	 Institut	 Universitair	 d’Hématologie	





lncRNA	 profiling.5,	 19	 The	 T-ALL	 cell	 lines	





dergoing	 cardiac	 surgery	 (UZ	Gent)	 and	was	
obtained	 and	 used	 according	 to	 the	 guide-
lines	 of	 the	 Medical	 Ethical	 Commission	 of	
Ghent	 University	 Hospital	 (Ghent,	 Belgium).	
Both	 thymocyte	 subsets	 were	 each	 purified	
from	two	different	healthy	donors	in	order	to	
obtain	 two	 independent	 replicates	 for	 each	
subset.	 Immature	 CD34+	 thymocytes	 were	
purified	 based	 on	 MACS	 purification	 using	
CD34	 microbeads	 (Miltenyi	 Biotec)	 20	 while	
CD4	 and	 CD8	 labeling	 was	 used	 to	 sort	 the	
CD4+CD8+	 double	 positive	 subset	 using	 a	
FACSAriaIII	 (BDBiosciences).21	 The	 purity	 of	
each	subset	was	at	least	98%.	Total	RNA	was	
isolated	 using	 the	 miRNeasy	 mini	 kit	 (Qi-
agen).	
MicroRNA	 profiling	 by	 small	 RNA-
sequencing	
The	 libraries	 for	 small	 RNA-sequencing	were	
prepared	using	 the	TruSeq	small	RNA	 library	
kit	 from	 Illumina	with	50	ng	of	 total	RNA	as	
input	 for	 T-ALL	 samples	 and	 100	 ng	 of	 total	
RNA	as	 input	 for	T-ALL	cell	 lines	and	 thymo-
cyte	subset	samples.	According	to	the	manu-
facturer’s	 use,	 3’	 and	 5’	 RNA	 adapters	were	
ligated	to	the	RNA	followed	by	reverse	tran-
scription	 and	 PCR	 amplification	 (with	 bar-
coded	primers).	The	PCR	products	were	sepa-
rated	using	 a	Pippin	Prep	 System	 to	 recover	
the	147	nt	 and	157	nt	 fractions.	 Sequencing	
of	the	small	RNA	libraries	was	performed	on	
a	NextSeq500	 (Illumina),	with	 an	 average	 of	
14.4	 million	 reads	 per	 sample.	 After	 read	
quality	 control	 and	 adapter	 trimming,	 reads	
were	 mapped	 to	 the	 reference	 genome	






RNAs	detected	by	at	 least	4	reads	 in	at	 least	
60	%	of	samples	from	one	T-ALL	subgroup	or	
in	 at	 least	 all	 samples	 from	 one	 thymocyte	








ples,	 healthy	 donor	 thymocytes	 and	 T-ALL	
cell	lines		
To	 study	 the	 full	 spectrum	 of	 miRNAs	 in-
volved	 in	normal	and	malignant	T-cell	devel-
opment,	 we	 performed	 small	 RNA-
sequencing	on	48	primary	T-ALL	patient	sam-
ples	 of	 different	 T-ALL	 subgroups	 (13	 imma-
ture,	 14	 TLX1+	 or	 TLX3+,	 15	 TAL-rearranged	
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miRNA expression vs isomiRs
r = 0.89
	172	




miRNA	 expression	 profiling	 was	 done	 previ-
ously	using	an	RT-qPCR	approach	10,	we	were	
able	 to	 directly	 compare	 the	 absolute	 num-
ber	 of	 detected	 miRNAs	 between	 the	 RT-
qPCR	 and	 small	 RNA-sequencing	 platforms.	
Using	a	similar	background	selection	as	men-
tioned	above,	283	miRNAs	were	detected	by	
RT-qPCR	 10,	 which	 reflects	 about	 half	 of	 the	
miRNA	 transcripts	 that	 were	 identified	 by	
small	 RNA-sequencing.	 Next,	 we	 converted	
the	 miRNA	 annotation	 of	 the	 RT-qPCR	 plat-
form	 to	 the	most	 recent	 annotation	 in	miR-
Base	 by	 using	 the	miRBaseTracker	 25,	 which	
resulted	in	248	unique	miRNAs.	There	was	an	
overlap	 of	 198	 miRNAs	 with	 small	 RNA-




the	 574	 miRNAs,	 detected	 by	 small	 RNA-
sequencing	 in	 primary	 T-ALL	 patients,	 are	
plotted,	with	the	black	dots	representing	the	
280	 miRNAs	 that	 were	 previously	 identified	
by	 RT-qPCR	 and	 the	 red	 dots	 representing	
the	miRNAs	detected	 for	 the	 first	 time	 in	 T-
ALL	 samples.	 Most	 of	 the	 formerly	 known	
miRNAs	 reside	 amongst	 the	most	 highly	 ex-
pressed	 in	human	T-ALL	 (Figure	1b).	Howev-
er,	some	of	the	newly	T-ALL	identified	miRNA	
transcripts	 also	 show	a	 very	 high	 expression	
pattern	 (the	 top	 10	 of	 highest	 expressed	
novel	 miRNAs	 are	 annotated	 in	 Figure	 1b),	
suggesting	that	they	might	possess	oncogenic	
potential	in	the	context	of	T-ALL	disease	biol-
ogy.	 Nevertheless,	 the	 average	 expression	
level	of	most	novel	 T-ALL	miRNAs	 that	were	
exclusively	 detected	 by	 small	 RNA-
sequencing	is	median	to	low.		
Small	 RNA-sequencing	 also	 enables	 the	 de-
tection	 of	 so-called	 isomiRs,	 i.e.	 miRNA	
isoforms	 that	deviate	 from	the	canonical	 se-
quence	by	one	or	a	few	nucleotide(s).11,	12	 In	
our	small	RNA-sequencing	dataset,	we	identi-
fied	 2139	 isomiRs	 covering	 481	 different	
miRNAs,	 losing	 some	 very	 low	 expressed	
miRNAs	 from	 the	 analysis	 above.	 	 Although	
154	 miRNAs	 were	 only	 represented	 by	 one	
isomiR,	 some	 others	 showed	 expression	 of	
more	 than	10	different	 isomiR	 forms	 (Figure	
1c).	 We	 observed	 a	 positive	 correlation	 be-
tween	the	number	of	 isomiRs	detected	for	a	
specific	 miRNA	 and	 its	 expression	 level	 in	
human	T-ALL	(r	=	0.89,	Figure	1d).	For	exam-
ple,	 we	 detected	 39	 different	 isomiR	 forms	
for	miR-181a-5p,	 the	miRNA	 that	 shows	 the	
highest	average	expression	in	T-ALL.	Remark-
ably,	for	106	out	of	481	miRNAs,	the	canoni-
cal	miRNA	was	 not	 expressed	 in	 our	 patient	
series.	 In	 addition,	 for	 only	 half	 of	 the	miR-
NAs	 (246	 out	 of	 481),	 the	 canonical	 isoform	
showed	the	highest	expression	level,	suggest-
ing	that	a	substantial	amount	of	miRNAs	are	
mainly	 represented	 by	 alternative	 isomiRs.	
The	 distribution	 of	 isomiRs	 that	 show	 the	
highest	expression	 for	each	miRNA	 is	 shown	
in	Figure	1e.		
Small	 RNA-sequencing	 reveals	 a	 subtype	
specific	 expression	 pattern	 of	 miRNAs	 in	
human	T-ALL	
Previous	 studies	 have	 convincingly	 shown	
that	molecular	genetic	subtypes	of	human	T-
ALL	 display	 unique	 mRNA	 1,	 2	 and	 lncRNA	 5	
expression	signatures.	Here,	we	used	the	574	
















<	 0.05;	 Figure	 2a;	 Supplementary	 Table	 1).	
Principal	Component	Analysis	confirmed	that	
the	 most	 pronounced	 differences	 in	 miRNA	







As	 mentioned	 above,	 small	 RNA-sequencing	
was	also	performed	on	a	panel	of	7	human	T-




(PF-382,	 JURKAT	 and	 KE-37)	 and	 imma-
ture/HOXA	 overexpressing	 (LOUCY)	 tumor	
lines.	 Notably,	 subtype	 specific	 miRNAs,	
which	 were	 identified	 in	 primary	 T-ALL	 pa-
tient	samples,	also	showed	high	expression	in	
the	T-ALL	cell	 lines	 from	their	corresponding	
genetic	 subtype	 (Figure	 2d	 and	 Supplemen-
tary	Figure	1).	Therefore,	the	subtype	specific	
tumor	 lines	 can	 be	 used	 as	 valuable	 in	 vitro	
tools	to	evaluate	the	role	of	specific	miRNAs	
in	the	pathogenesis	of	this	disease.		
MiRNA	 profiling	 of	 normal	 thymocyte	 sub-
sets	 reveals	 oncogenic	 subtype	 specific	
miRNAs	
Small	 RNA-sequencing	 was	 also	 performed	
on	 CD34+	 and	 CD4+CD8+	 normal	 thymocyte	
samples	 from	 two	 healthy	 donor	 controls.	
First,	 DESeq2	 analysis	 revealed	 190	 miRNAs	
that	 show	 significant	 differential	 expression	




most	 significant	 miRNAs	 are	 listed	 in	 Figure	
3b,	 with	 the	 miRNAs	 depicted	 in	 red	 those	
that	 were	 not	 covered	 in	 previous	 RT-qPCR	
analyses.	Of	note,	small	RNA-sequencing	data	












































































were	 highly	 concordant	 between	 both	 do-





in	 the	 primary	 T-ALL	 patient	 cohort.	 For	 ex-
ample,	 4	miRNAs	 (hsa-miR-222-3p,	 hsa-miR-
146a-5p,	 hsa-mir-221-3p	 and	 hsa-miR-126-
5p)	 from	the	top	10	 immature	T-ALL	specific	
miRNAs	 (Figure	 2c)	 also	 showed	 significant	
higher	 expression	 in	 CD34+	 vs.	 CD4+CD8+	 T-
cell	 subsets	 (Figure	4a).	Similarly,	 three	miR-
NAs	 (hsa-miR-16-5p,	 hsa-miR-16-2-3p	 and	
hsa-miR-450b-5p)	from	the	top	10	TAL-R	spe-
cific	miRNAs	 (Figure	 2c)	 are	 significantly	 up-
regulated	 in	 CD4+CD8+	 T-cell	 subsets	 (Figure	
4b).	Therefore,	 these	miRNAs	most	probably	
reflect	 the	 specific	 T-cell	 maturation	 arrest	
associated	with	these	molecular	genetic	sub-
types	 of	 T-ALL	 and	 their	 respective	 cell	 of	
origin.		
In	 order	 to	 identify	miRNAs	with	 true	 onco-
genic	 potential	 in	 specific	 T-ALL	 subgroups,	
we	 also	 performed	 differential	 expression	
analysis	between	immature	T-ALLs	and	CD34+	
thymocytes,	 and	 between	 TAL-R	 T-ALLs	 and	
CD4+CD8+	 thymocytes,	 as	 these	 thymocyte	
subsets	represent	the	stage	of	differentiation	
arrest	 during	 T	 cell	 development	 leading	 to	
these	 specific	 T-ALL	 subtypes	 	 (Supplemen-
tary	Tables	3	and	4).	From	the	top	ten	imma-
ture	specific	miRNAs,	three	miRNAs	(hsa-miR-
21-5p,	 hsa-miR-222-3p	 and	 hsa-miR-101-3p)	
were	 significantly	 upregulated	 in	 the	 imma-
ture	 samples	 compared	 to	 the	 healthy	 con-
trol	 CD34+	 samples.	 Remarkably,	 hsa-miR-
222-3p	 was	 also	 significantly	 upregulated	 in	
the	CD34+	subset,	but	its	expression	is	further	
increased	 in	 immature	 T-ALLs	 (Figure	 4c).	

































































hsa-miR-29c-3p	 and	 hsa-miR-450b-5p),	 from	
the	 TAL-R	 subtype	 specific	 signature,	 show	
significant	 higher	 expression	 in	 the	 TAL-R	 T-




crease	 in	 activity	 in	TAL-R	 rearranged	 leuke-
mias	(Figure	4d).		
Small	 RNA-sequencing	 reveals	 putative	 on-
cogenic	miRNAs	in	human	T-ALL		
Finally,	 we	 aimed	 to	 identify	 novel	 T-ALL	
miRNAs	 with	 potential	 oncogenic	 activity	 in	
human	T-ALL	irrespective	of	the	genetic	sub-
types.	 Differential	 expression	 analysis	 be-
tween	 48	 T-ALL	 samples	 and	 four	 normal	
thymocyte	 samples	 (Supplementary	 Table	5)	
resulted	in	the	identification	of	87	significant-
ly	upregulated	miRNAs	and	69	downregulat-
ed	miRNAs	 in	human	T-ALL	 (Figure	5a).	 Sev-
eral	miRNAs	with	a	known	oncogenic	 role	 in	
T-ALL	 8,	26	were	 recovered	 from	 this	 analysis	
and	are	depicted	 in	 Figure	5a.	However	 and	
most	notably,	this	analysis	also	identified	dif-








Soulier	 et	 al.	 described	 different	 T-ALL	 sub-
types	 according	 to	 specific	 transcriptional	
profiles.1,	2	 Last	 year,	we	were	 able	 to	 show	
that	 these	 molecular	 genetic	 subtypes	 of	
human	 T-ALL	 also	 display	 unique	 long	 non-
coding	RNA	expression	signatures.5	Here,	we	
performed	 small	 RNA-sequencing	 on	 48	 T-
ALL	patient	samples	to	finalize	the	transcrip-







































































































ly	 detected	miRNAs	 were	 expressed	 at	 very	
low	 levels,	 we	 also	 identified	 a	 selection	 of	
novel	 T-ALL	 miRNAs	 with	 very	 high	 expres-
sion	levels	in	T-ALL	patient	samples,	including	
hsa-miR-181b-5p,	 hsa-miR-423-3p,	 hsa-miR-




ample,	 hsa-miR-181b-5p	 is	 a	 known	 onco-
gene	 in	 several	 cancer	 types	 as	 reviewed	by	
Liu	et	al..27	 In	the	context	of	 leukemia,	over-
expression	of	hsa-miR-181b-5p	was	shown	to	
enhance	 proliferation	 in	 acute	 myeloid	 leu-
kemia	by	 targeting	MLK2.	 Furthermore,	hsa-
miR-92b-3p	was	 identified	 as	 an	 oncomiR	 in	
glioblastoma	 by	 targeting	 SMAD3	 (ref.	 28),	
which	is	known	to	be	lost	 in	several	cases	of	
pediatric	T-ALL	(ref.	29),	and	PTEN	(ref.	30),	a	
well-established	 T-ALL	 oncosuppressor.31,	 32	
In	addition,	hsa-miR-92b-3p	is	also	specifical-
ly	 higher	 expressed	 in	 TLX1/3	 T-ALL	 com-
pared	to	the	other	T-ALL	subtypes.	
Interestingly,	 small	 RNA-sequencing	 also	 de-
tects	 deviations	 from	 canonical	 miRNA	 se-




expression	 (Figure	 1e).	 In	 addition,	 most	
highly	expressed	 isomiRs	displayed	modifica-
tions	at	their	3’	end,	suggesting	that	these	al-
terations	 would	 not	 affect	 the	 miRNA	 seed	
sequence	and,	 therefore,	have	no	 functional	
effect	 on	 target	 recognition.	Nevertheless,	 a	
number	of	 studies	have	shown	that	 these	3’	
modifications	might	 impact	 target	 specificity	
and	stability	of	the	miRNA.17,	33	
Finally,	 small	 RNA	 sequencing	 of	 human	
CD34+	and	CD4+CD8+	thymocytes	enabled	the	
identification	 of	 subtype	 specific	 and	 onco-
genic	miRNAs	in	the	context	of	human	T-ALL.	
An	 interesting	 example	 is	hsa-miR-486.	Hsa-
miR-486-5p	 is	 one	 of	 the	 highest	 expressed	
newly	 identified	miRNAs	 in	T-ALL	 (Figure	1b)	




myeloid	 leukemias,	 where	 it	 is	 regulated	 by	







molecular-genetic	 subtypes	 of	 human	 T-ALL.	
Integration	 of	 these	 signatures	 with	 miRNA	
expression	 profiles	 in	 normal	 T-cell	 subsets	
provides	 a	 unique	 resource	 to	 study	 novel	
miRNAs	 that	 are	 implicated	 in	 T-ALL	 disease	
biology.		
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Supplementary Figure 1. Subtype specific miRNAs are also represented in the T-ALL cell lines. Den-
sity plots representing the distribution of the miRNA expression in the T-ALL cell lines DND-41, ALL-SIL, 
PF-382 and KE-37. Vertical bars show the expression level of the top 10 miRNAs selected for the subgroup 
these cell lines represent. DND-41 (A) and ALL-SIL (B) for the TLX subgroup and PF-382 (C) and KE-37 (D) 







































miRNA expression in CD34+ samples
r = 0.98
Supplementary Figure 2. miRNA expression is highly correlated in 2 different donors. Scatterplots 
representing the log2 normalized expression of the miRNAs profiled by small RNA-sequencing for 2 different 
donors of CD34+ thymocytes (A) and CD4+CD8+ thymocytes (B).


























































ed,	 first	 by	 cytogenetic	 and	 molecular	 cytogenetic	 techniques	 and	 more	 recently	 by	 next-
generation	 sequencing	 technologies.	 This	 led	 to	 the	 identification	 of	 several	 key	 oncogenic	
driver	mutations	and	allowed	to	identify	several	T-ALL	genetic	subtypes.	Also,	the	identification	
of	the	genes	implicated	in	T-ALL	provided	fundamental	insights	into	the	process	of	normal	and	
perturbed	 thymocyte	differentiation	 and	oncogenesis.	 Importantly,	 this	work	 also	offered	 in-
sights	into	novel	therapeutic	targets.	In	addition	to	protein	coding	genes,	the	role	of	noncoding	
RNAs	in	T-ALL	has	also	received	growing	attention.	Previous	studies	of	the	host	lab	and	others	









by	a	 subtype	 specific	 gene	expression	profile	 (paper	 2).	As	next-generation	 sequencing	 tech-






selves.	 However,	 previous	 studies	 could	 not	 define	 these	 profiles	 after	 RT-qPCR	 profiling	 of	
miRNA	 expression	 in	 a	 primary	 T-ALL	 patient	 cohort.	 Therefore,	 I	 performed	 small	 RNA-
sequencing	on	48	primary	patient	samples	to	detect	a	broader	range	of	miRNAs	than	previous	
studies	and	with	this	dataset	I	was	then	able	to	find	miRNAs	with	a	specific	expression	in	T-ALL	






IMMATURE TLX1/3 TAL-R HOXA
Figure	11.	Overview	of	the	primary	T-ALL	patient	samples	used	in	this	thesis.	The	patient	samples	from	the	same	







The	NOTCH1-signaling	pathway	 is	of	major	 interest	 in	T-ALL	 research	as	 it	 is	overactivated	 in	




opment2.	Overactivation	of	this	signaling	pathway	or	 ligand	 independent	signaling	 leads	how-







is	 due	 to	 the	 presence	 of	 the	 NOTCH1	 and	 NOTCH2	 receptors	 on	 the	 intestinal	 epithelium,	
which	are	both	targeted	by	GSIs.	In	this	PhD	thesis,	I	used	a	GSI	(Compound	E)	as	a	tool	to	inhib-
it	NOTCH1-signaling	 in	vitro	 in	the	T-ALL	cell	 line	CUTLL1	and	evaluated	the	transcriptional	ef-
fects	on	downstream	lncRNA	expression	(see	paper	1).	Next	to	that,	we	activated	NOTCH	sig-
naling	 in	 CD34+	 T-cells	 by	 growing	 them	 on	 a	 feeder	 layer	 containing	 the	 DLL1-ligand.	 The	
NOTCH1-activated	lncRNAs	were	further	studied	in	different	T-ALL	cell	lines,	T-ALL	patient	sam-
ples	and	T-cell	subsets	that	were	profiled	by	a	custom	designed	micro-array	platform	detecting	
the	 expression	 of	 mRNAs	 and	 lncRNAs.	 Publicly	 available	 ICN1	 (activated	 NOTCH1)	 ChIP-












so-called	 ‘guilt-by-association’	analysis	 to	 identify	 the	pathways	 these	 lncRNAs	are	 correlated	















between	 the	 LUNAR1	 promoter	 and	 an	 active	 enhancer	 in	 the	 last	 intron	 of	 its	 neighboring	
gene	IGF1R.	The	knockdown	of	LUNAR1,	but	not	its	overexpression,	could	modulate	the	IGF1R	
expression,	 showing	 a	 cis-regulatory	 effect.	 Furthermore,	 it	was	 shown	 that	 LUNAR1	was	 in-
volved	in	the	recruitment	of	the	Mediator	complex	and	RNAPII	to	the	IGF1R	enhancer,	leading	
to	increased	IGF1R	expression.		
Briefly	 after	 the	 discovery	 of	 LUNAR1,	 another	 lncRNA	 was	 linked	 to	 the	 NOTCH1-pathway	
(NOTCH1-associated	 lncRNA	 in	 T-ALL	 or	 NALT).	 The	 NALT	 transcript	 is	 bi-directionally	 tran-
scribed	from	the	NOTCH1	locus10.	The	knockdown	of	NALT	in	vitro	and	in	vivo	inhibited	cell	pro-
liferation,	potentially	due	 to	cis-regulation	of	NOTCH1	mRNA	 transcription	as	 it	 showed	a	 re-
duction	in	the	NOTCH1	downstream	targets.	This	study	thus	further	provides	another	example	
that	lncRNAs	might	play	a	crucial	role	in	NOTCH1-driven	signaling.	NALT	knockdown	might	be	a	



















have	 been	 described	 that	 define	 the	 signature	 of	 a	 particular	 subtype	 such	 as	 TLX1	 or	 TLX3	
overexpression,	 TAL1-rearrangements	 or	 HOXA	 overexpression.	 These	 oncogenic	 events	 are	

















tent	candidates	as	novel	players	 in	T-ALL	development.	Therefore,	 I	dissected	 lncRNA	expres-
sion	profiles	obtained	from	64	primary	T-ALL	patients	by	means	of	a	custom	in-house	designed	








identified	as	 significantly	upregulated	 in	 the	HOXA	 subtype.	Repeating	 the	 same	analyses	 for	
the	 lncRNAs	detected	on	 the	micro-array	platform,	 also	 allowed	 to	detect	 a	 subtype	 specific	
expression	pattern,	but	with	only	a	small	amount	of	 lncRNAs	 in	 the	HOXA	signature.	Further,	
mRNA	 and	 lncRNA	 expression	 profiles	 of	 different	 T-ALL	 cell	 lines,	 linked	 to	 the	 immature,	
TLX1/3	or	TAL-R	 subtype	were	also	 included	allowing	 to	validate	 in	 those	 in	vitro	models	 the	
subtype	specific	 lncRNA	expression	patterns	 identified	 from	patient	samples.	Finally,	by	using	









the	 subtypes	 defined	 by	 mRNA	 profiling	 had	 specific	 lncRNA	 expression	 profiles	 and	 these	
lncRNA	profiles	could	also	predict	the	subtype	of	a	validation	cohort.	Furthermore,	they	identi-
fied	BALR-2		(‘B-ALL	associated	long	RNA-2’)	as	an	lncRNA	linked	to	poor	prognosis	and	reduced	












scripts.	These	topics	are	of	specific	 interest	for	 lncRNA	research	as	 lncRNA	are	expressed	at	a	
much	lower	level	than	most	protein	coding	genes	and	several	novel	lncRNAs	are	being	detected	
as	they	are	only	expressed	in	a	specific	tissue	or	disease.	





RNA-seq	 based	 generation	 of	 expression	 profiles	 was	 more	 challenging.	 However,	 from	 the	
matching	lncRNAs	I	could	identify	several	that	were	significantly	differentially	expressed	in	a	T-
ALL	 subtype	 compared	 to	 the	 others	 by	 both	methods.	 Interestingly,	 the	 lncRNAs	 that	were	
subtype	specific	in	both	methods,	were	identified	with	a	larger	fold	change	in	the	poly(A)	RNA-
sequencing	dataset	compared	to	the	micro-array	dataset.	This	is	consistent	with	previous	publi-
cations	 that	 also	 detected	 a	 larger	 difference	with	 RNA-sequencing	 technologies.	One	of	 the	
major	advantages	of	RNA-sequencing	in	lncRNA	research	is	the	possibility	to	detect	novel,	pre-













notated	lncRNAs.	 Indeed,	as	 it	has	been	estimated	that	about	one	third	of	all	 lncRNAs	do	not	
have	a	poly(A)	tail,	a	significant	additional	number	of	lncRNAs	should	be	detected	using	this	ap-
proach.	 As	 a	 side	 note,	 it	 should	 be	 mentioned	 that	 also	 some	 known	 non-polyadenylated	







17	%	more	novel	 lncRNAs	 than	poly(A)	RNA-seq	and	next	 to	 that,	 total	RNA-seq	also	detects	
more	annotated	lncRNAs.	It	might	also	be	interesting	to	check	for	the	presence	of	circular	RNAs	
(circRNAs)	 in	 this	 total	RNA-seq	dataset,	as	 these	are	not	detected	by	poly(A)	RNA-seq.	Total	






















cro-peptides	or	as	 they	might	be	by-products	of	 transcription	of	nearby	genes.	A	very	 recent	
paper	by	the	Proudfoot	team	studied	the	transcription	and	RNA-processing	of	lincRNAs	(inter-
genic	lncRNAs)	and	identified	several	differences	in	comparison	to	pre-mRNA	transcription	and	
processing.	 Of	 particular	 interest,	 they	 state	 that	 lincRNAs	 are	 unstable	 and	 cleaved	 during	
transcription24.	This	is	one	of	the	papers	that	illustrates	that	lncRNA	research	is	only	a	very	re-
cent	 scientific	 field	 and	 a	 lot	 remains	 to	 be	 explored.	 Certainly,	 not	 all	 detected	ncRNAs	will	





and	need	to	be	studied	 in	detail	by	other	technologies,	 for	example	CAGE-seq	to	 identify	 the	






databases	make	use	of	different	 identifiers	 for	 the	same	 lncRNA	 locus,	which	 further	compli-
cates	lncRNA	research.		
A	crucial	next	step	towards	 the	 identification	of	 the	 function	of	an	 lncRNA	 is	 through	 in	vitro	
knockdown	or	knockout	of	lncRNA	expression.	For	knockdown,	the	use	of	the	RNA	interference	
machinery	with	siRNAs	(short	 interfering	RNAs)	or	shRNAs	(short	hairpin	RNAs)	may	not	work	
as	 they	make	use	of	 the	DICER	machinery	of	 the	miRNA	biogenesis	pathway,	which	 is	mostly	
functional	 in	the	cytoplasm.	Therefore,	 the	use	of	antisense	oligonucleotides	(ASOs)	 is	a	valid	
alternative	option,	as	these	are	 functional	 in	the	nucleus	by	using	the	RNaseH	enzyme	to	de-
grade	the	RNA	molecule.	CRISPR-mediated	knockout	is	another	option	but	may	be	hampered	in	
subsequent	phenotypic	 interpretation	as	 lncRNAs	 can	overlap	with	protein	 coding	 genes	 (ex.	
antisense	 lncRNAs)	 or	with	 regulatory	 regions	 (ex.	 enhancers).	 Alternatively,	 lncRNAs	 can	 be	

































the	 first	 time	 the	 miRNA	 expression	 of	 a	 large	 cohort	 of	 primary	 T-ALL	 patient	 samples	 by	



















tion),	 the	seed	sequence	changes,	which	has	a	major	 impact	on	the	target	 recognition	of	 the	
miRNA.	However,	in	this	dataset,	I	mostly	detected	isomiR	forms	that	have	an	addition	or	dele-
tion	of	one	or	more	nucleotides	at	 the	3’	end,	which	does	not	 immediately	affect	 the	 target	
recognition	 site	of	 the	miRNA.	 The	3’	 end	 isomiR	 variants	 are	 also	 in	other	 studies	 the	most	
common	detected	modifications33-36,	but	their	functional	mechanism	is	less	clear	than	for	the	5’	
isomiRs.	 It	was	however	discovered	that	3’	 isomiRs	can	have	a	different	affinity	 for	 the	AGO-
complexes	as	the	canonical	miRNAs,	which	can	have	an	effect	on	the	mRNA	modulation	(as	for	
example	only	AGO2	is	able	to	cleave	the	target	mRNA)33.	Furthermore,	it	was	already	described	
















ferential	 expression	 analyses	 are	 available	 as	 supplementary	materials	 for	 the	 papers,	which	
makes	these	results	available	for	a	quick	examination.	
This	study	was	the	first	RNA-seq	based	characterization	of	a	large	T-ALL	patient	cohort	for	both	
miRNA	 and	 lncRNA.	 Further,	 the	 poly(A)	 and	 total	 RNA-sequencing	 data	 can	 also	 be	 used	 to	














explain	 a	 possible	 activation	 or	 repression	 of	 the	 subtype	 specific	 lncRNA/miRNA	 by	mRNAs	
linked	 to	 the	same	subtype	 (Figure	12	B).	A	 third	and	 final	example	 I	would	 like	 to	point	out	
here	 is	 the	 identification	 of	 competing	 endogenous	 RNAs	 (ceRNAs),	 which	 are	 lncRNAs	 that	
bind	miRNAs,	acting	as	sponges	and	titrating	them	away	from	their	mRNA	target,	leading	to	the	
















Figure	12.	Future	research	directions	using	 the	datasets	provided	 in	 this	 thesis.	 (A)	Negative	correlation	with	a	
miRNA	might	point	at	a	miRNA	target.	(B)	Positive	or	negative	correlation	with	a	transcription	factor	might	indicate	
transcriptional	 regulation.	 (C)	An	mRNA	and	 lncRNA	that	are	both	upregulated	 in	a	specific	group	and	that	have	
binding	 sites	 for	 the	 same	 miRNA	 might	 identify	 the	 lncRNA	 as	 a	 ceRNA.	 (Illustrations	 from	
www.somersault1824.com)		
help	in	identifying	true	oncogenic	pathways.	Next	to	that,	online	available	gene-expression	da-
tasets	 might	 aid	 in	 the	 identification	 of	 cancer	 type	 or	 tissue	 type	 specific	 lncRNAs.	 For	
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Normal	T-cell	development	 is	a	hierarchically	orchestrated	process	and	 requires	 strict	 regula-
tion	of	underlying	gene	expression	programs.	Various	genomic	lesions	can	lead	to	either	aber-
rant	expression/activation	of	proto-oncogenes	or	repression/loss	of	tumor	suppressors	that	in-







ficient	 and	 less	 toxic	 targeted	 therapies.	 During	my	 PhD	mandate,	 I	 explored	 the	 expression	
patterns	of	two	types	of	noncoding	RNAs,	lncRNAs	and	miRNAs,	in	T-ALL	patient	samples,	sort-
ed	 T-cell	 subsets	 and	 T-ALL	 in	 vitro	 models	 as	 their	 functional	 role	 in	 cancer	 biology	 has	
emerged	strongly	in	the	last	decades	and,	particularly	for	lncRNAs,	their	role	in	T-ALL	remained	
largely	 unexplored.	 This	 thesis	 provides	 a	 unique	 resource	 depicting	 the	miRNA	 and	 lncRNA	






clinical	 trials	unfortunately	 failed	as	a	consequence	of	 therapy	resistance	and	gastrointestinal	






more,	 the	mRNA	 expression	 profiles	 of	 T-ALL	 cases	 cluster	 together	 according	 to	 subtype.	 I	
aimed	 in	 the	 second	part	of	my	PhD	 thesis	 to	explore	 the	expression	of	 lncRNAs	next	 to	 the	
protein	coding	gene	expression	for	each	of	the	known	T-ALL	subtypes	by	means	of	micro-array	
technology	 and	 I	 could	 show	 that	 the	 T-ALL	 subgroups	 are	 also	 characterized	 by	 a	 specific	
lncRNA	 expression	 profile,	 adding	 a	 novel	 layer	 of	 gene	 signatures	 that	 characterize	 these	
groups.	Through	a	comparative	analysis	with	lncRNA	expression	profiles	of	sorted	healthy	do-









samples,	 that	we	previously	 screened	by	means	of	micro-array	 technology,	using	poly(A)	and	
total	RNA-sequencing.	Comparative	analysis	with	the	array	based	technology	showed	that	RNA-
sequencing	allows	detection	of	differentially	expressed	lncRNAs	with	a	larger	fold	change	thus	





T-ALL.	Different	 research	 teams,	 including	 the	host	 lab,	 already	 studied	 the	 role	of	 individual	
miRNAs	and	mRNA-miRNA	networks	 in	T-ALL.	 In	 this	 thesis,	a	pioneering	study	was	set	up	to	
evaluate	 subtype	 specific	 miRNA	 expression	 patterns	 of	 T-ALL	 patient	 samples	 by	 means	 of	






To	 conclude,	 with	 this	 PhD	 project	 I	 established	 unique	 noncoding	 RNA	 expression	 datasets	
(miRNA	 and	 lncRNA)	 and	 identified	 potential	 oncogenic	 miRNAs	 and	 lncRNAs	 in	 T-ALL	 that	

















(T-ALL)	verhoogt.	Door	een	 intensieve	behandeling	 is	de	prognose	voor	T-ALL	patiënten	 in	de	










een	 functionele	 rol	 voor	 kandidaat	miRNAs	en	 lncRNAs	betrokken	 in	T-ALL	als	mogelijke	bio-
merkers	of	nieuwe	therapeutische	doelwitten.	




































ik	mijn	doctoraatsstudie	heb	uitgevoerd,	hebben	al	de	 rol	 van	 individuele	miRNAs	en	mRNA-
miRNA	netwerken	 in	T-ALL	bestudeerd.	 In	deze	thesis	werd	een	eerste	studie	opgezet	om	de	








Samengevat	 heb	 ik	met	 dit	 doctoraatsproject	 unieke	 niet-coderende	 RNA	 expressie	 datasets	
(miRNAs	en	lncRNAs)	gegenereerd	en	mogelijke	oncogene	miRNAs	en	lncRNAs	in	T-ALL	geïden-
tificeerd	 die	 gebruikt	 kunnen	 worden	 voor	 verder	 functioneel	 en	 therapeutisch	 onderzoek.	
Aangezien	er	al	voor	verscheidene	therapieën	gericht	tegen	niet-coderende	RNAs	(miRNAs	en	
lncRNAs)	(pre-)	klinische	studies	opgestart	zijn,	kan	de	identificatie	van	miRNAs	en	lncRNAs	met	

















FWO	 mandaat	 met	 succes	 kon	 binnenrijven.	 Zijn	 enthousiasme	 voor	 het	 kankeronderzoek	
werkte	zeer	aanstekelijk	en	de	manier	waarop	hij	snel	een	nieuw	en	goed	project	kon	bedenken	
was	 zeer	 inspirerend.	Verder	 zal	 ik	 ook	blijven	onthouden	dat,	 alhoewel	 hij	 vaak	 van	de	ene	
naar	de	andere	vergadering	spurtte	en	zijn	stoel	 in	onze	bureau	zo	goed	als	ongebruikt	 is,	hij	
toch	een	zeer	bereikbare	prof	was.	Ook	mijn	co-promotoren	waren	van	groot	belang	voor	het	
slagen	 van	 dit	 project.	 In	 eerste	 instantie	 zorgde	 dr.	 Pieter	 Rondou	 ervoor	 dat	 ik	 door	mijn	
masterthesis	de	microbe	van	het	wetenschappelijk	onderzoek	te	pakken	kreeg,	zorgde	hij	voor	























































































































• EV-TRACK:	 transparent	 reporting	and	 centralizing	knowledge	 in	extracellular	 vesicle	 re-
search.	 EV-TRACK	 Consortium.	 Van	 Deun	 J,	 Mestdagh	 P,	 Agostinis	 P,	 Akay	 Ö,	 Anand	 S,	



























• Comprehensive	miRNA	expression	profiling	 in	 human	T-cell	 acute	 lymphoblastic	 leuke-





































































tic	 targeting.	Wallaert	 A,	Durinck	 K,	Van	 Loocke	W,	Volders	 PJ,	Van	 de	Walle	 I,	 Benoit	 Y,	
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